

STIC-Biotech/ChemLib

93134

From: Stucker, Jeffrey
Sent: Monday, May 05, 2003 10:36 AM
To: STIC-Biotech/ChemLib
Subject: 09/868399

Please search SEQ ID NO 1. The peptide is limited to no more than 60 amino acids in the claims.

Thanks,
Jeff Stucker
1648
308-4237
mail: 8E12

RECEIVED
MAY - 5 2003
STIC/CHEM LIBRARY
(STIC)

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: 5/12/03
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:

NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)

STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____

THIS PAGE BLANK (USPTO)

GenCore version 5.1.4 p5 4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 6, 2003, 14:55:59 ; Search time 29 Seconds
(without alignments)
255.783 Million cell updates/sec

Title: US-09-868-399-1

Perfect score: 198
Sequence: 1 KIQNFRVYRDSRDLWKGPALKLMKGGAIVIQDN 36

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 124338

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

SPTREMBL_21:*

- 1: sp_archaea:*
- 2: sp_bacteria:*
- 3: sp_fungi:*
- 4: sp_human:*
- 5: sp_invertebrate:*
- 6: sp_mammal:*
- 7: sp_mhc:*
- 8: sp_organelle:*
- 9: sp_phage:*
- 10: sp_plant:*
- 11: sp_rodent:*
- 12: sp_virus:*
- 13: sp_vertebrate:*
- 14: sp_unclassified:*
- 15: sp_virus:*
- 16: sp_bacteriap:*
- 17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	147	74.2	90	15	Q88124 chimpanzee
2	147	74.2	90	15	Q88130 chimpanzee
3	112	56.6	93	15	Q87646 chimpanzee
4	56	28.3	59	15	Q90071 chimpanzee
5	53.5	27.0	70	16	P70950 bacillus su
6	51	25.8	96	6	Q9BE76 macaca fasc
7	50.5	25.5	91	16	Q97KS3 clostridium
8	50	25.3	44	15	Q71895 human immun
9	50	25.3	44	15	Q71902 human immun
10	50	25.3	44	15	Q71909 human immun
11	50	25.3	44	15	Q71916 human immun
12	50	25.3	44	15	Q71923 human immun
13	50	25.3	44	15	Q71929 human immun
14	50	25.3	44	15	Q71936 human immun
15	50	25.3	44	15	Q71942 human immun
16	50	25.3	44	15	Q71874 human immun

17	50	25.3	44	15	Q71879 human immun
18	50	25.3	44	15	Q71885 human immun
19	50	25.3	44	15	Q71889 human immun
20	50	25.3	44	15	Q71967 human immun
21	50	25.3	44	15	Q71972 human immun
22	50	25.3	44	15	Q71978 human immun
23	50	25.3	44	15	Q71986 human immun
24	50	25.3	44	15	Q71997 human immun
25	50	25.3	44	15	Q72004 human immun
26	50	25.3	44	15	Q72012 human immun
27	50	25.3	57	5	Q9TX09 geodia cydo
28	49	24.7	77	12	Q8V2L8 camelpox vi
29	48.5	24.5	95	16	Q9X0G0 neisseria m
30	45	22.7	44	15	Q72008 human immun
31	45	22.7	44	15	Q72018 human immun
32	45	22.7	65	15	Q04098 simian t-ce
33	45	22.7	82	16	Q92XC8 rhizobium m
34	44	22.2	44	15	Q71991 human immun
35	44	22.2	80	4	O15521 homo sapien
36	43.5	22.0	47	4	Q96CJ4 Oshu87 homo sapien
37	43	21.7	52	4	Q9UH87 Oshu87 homo sapien
38	43	21.7	62	4	Q96FS0 homo sapien
39	43	21.7	77	13	Q90XF4 coturnix co
40	42.5	21.5	48	11	Q925T2 mus musculu
41	42	21.2	60	16	Q98CP2 rhizobium l
42	42	21.2	76	16	Q8SC0 anabaena sp
43	41.5	21.0	96	16	Q91C5 pseudomonas
44	41	20.7	94	16	Q31639 bacillus su
45	40.5	20.5	38	4	Q9BXG9 Oshx9 homo sapien

ALIGNMENTS

RESULT 1

Q88124 PRELIMINARY; PRT; 90 AA.

AC Q88124;

DT 01-NOV-1996 (TREMBLrel. 01, Created)

DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)

DT 01-MAR-2002 (TREMBLrel. 20, Last annotation update)

DE Pol polypeptide (Fragment).

GN GAG-POL OR POL.

OS Chimpanzee immunodeficiency virus (SIV/cpz) (CIV).

CC Viruses; Retroviral viruses; Retroviridae; Lentivirus.

OX NCBI_taxonomy=11723;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=90272009; PubMed=1971917;

RA Dewhurst S., Embretson J.E., Anderson D.C., Mullins J.I., Pultz P.N.;

RT "Sequence analysis and acute pathogenicity of molecularly cloned SIV."

RL Nature 345:636-640(1990).

CC -1- PTM: SPECIFIC ENZYMOLOGIC CLEAVAGES IN VIVO YIELD MATURE PROTEINS (BY SIMILARITY).

CC EMBL; I03296; AAA4761.1; -

DR InterPro; IPR01037; Integrase_C.

DR Pfam; PF00552; Integrase; 1.

KW Endonuclease; Hydrolase; Nucleotidyltransferase; Polypeptide;

FT RNA-directed DNA polymerase.

FT NON TER

FT SEQUENCE 90 AA; 10238 MW; 3FA32AB86D4B57FF CRC64;

Query Match 74.2%; Score 147; DB 15; Length 90;
Best Local Similarity 70.6%; Pred. No. 1.1e-13;
Matches 24; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

Cy 1 KIQNFRVYRDSRDLWKGPALKLMKGGAIVIQ 34
Db 16 KFNFRVYRDSRDLWKGPALKLMKGGAIVLK 49

RESULT 2

RA Boursier R., Boursier L., Brans A., Braun M., Brignell S.C., Bron S.,
 RA Brouillet S., Brusch C.V., Caldwell B., Capuano V., Carter N.M.,
 RA Choi S.K., Codani J.J., Connerion I.F., Cummings N.J., Daniel R.A.,
 RA Danizot F., Devine K.M., Dusterhoft A., Ehrlich S.D., Emerson P.T.,
 RA Entian K.D., Errington J., Fabret C., Ferrari E., Foulger D.,
 RA Fritz C., Fujita M., Fujita Y., Fuma S., Galizzi A., Galleron N.,
 RA Gilm S.Y., Glaser P., Goffeau A., Golightly E.J., Grandi G.,
 RA Giuseppe G., Guy B.J., Haga K., Halech J., Harwood C.R., Hernat A.,
 RA Hilbert H., Holmappell S., Hosono S., Hullo M.F., Itaya M., Jones L.,
 RA Joris B., Karamata D., Kasahara Y., Klier-Blanchard M., Klein C.,
 RA Kobayashi Y., Koetter P., Koningsstein G., Krogh S., Kumano M.,
 RA Kunita K., Lapius A., Lardinois S., Lauber J., Lazarevic V.,
 RA Lee S.M., Levine A., Liu H., Masuda S., Maue C., Medigic C.,
 RA Medina N., Melado R.P., Mizuno M., Moesti D., Nakai S., Packack M.,
 RA Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B., Park S.H.,
 RA Paro V., Pohl T.M., Portelle D., Portollik S., Prescott A.M.,
 RA Pressman E., Pujic P., Putnelle B., Rapoport G., Rey M., Reynolds S.,
 RA Rieger M., Rivolta C., Roche B., Roche B., Rose W., Sadate Y.,
 RA Sato T., Scanlan E., Schleich S., Schroeter R., Scoffone F.,
 RA Sekiguchi J., Sekowska A., Seror S.J., Seror P., Shin B.S., Soldo B.,
 RA Sorokini M., Tanakoshi A., Tanaka T., Terpestra P., Tognoni A.,
 RA Toso V., Uchiyama S., Vandembol M., Vannier F., Vassartot A.,
 RA Viart A., Wambutt R., Wedler B., Wedler H., Weitzengesser T.,
 RA Winters P., Wiput A., Yamamoto H., Yamane K., Yasumoto K., Yata K.,
 RA Yoshida K., Yoshikawa H.F., Zumbstein E., Yoshikawa H., Danchin A.,
 RT "The complete genome sequence of the gram-positive bacterium *Bacillus*
 RT subtilis";
 RL Nature 380:249-256(1997).
 DR EMBL; Z79580; CAB01839.1; -;
 DR EMBL; Y09476; CAI70635.1; -;
 DR EMBL; Z99109; CAB12957.1; -;
 KM Hypothetical protein; Complete proteome.
 SQ SEQUENCE 70 AA; 7757 MW; A3490E71E2CDD66 CRC64;

Query Match 27.0%; Score 53.5; DB 16; Length 70;
 Best Local Similarity 42.9%; Pred. No. 2.8;
 Matches 12; Conservative 5; Mismatches 10; Indels 1; Gaps 1;

Qy 6 RYRYRDSRPLMKGPALKMKGEAVI 33
 Db 44 RLTYR-RRPCKRTGKTIWMDAVV 70

RESULT 6
 Q9BE76 PRELIMINARY; PRT; 96 AA.
 AC Q9BE76; 01-JUN-2001 (TREMBlrel. 17, Created)
 DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
 DT 01-JUN-2001 (TREMBlrel. 17, Last annotation update)
 DE Hypothetical 10.7 kDa protein.
 OS Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Cercopitheidae;
 OC Cercopitheinae; Macaca.
 OX NCBI_TaxID=9541;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=BRAIN PARIETAL LOBE;
 RA Oada N., Hida M., Kusuda J., Tanuma R., Iseki K., Hirai M., Terao K.,
 RA Suzuki Y., Sugano S., Hashimoto K.;
 RT "Isolation of full-length cDNA clones from macaque brain cDNA
 RT libraries";
 RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AB056770; BAB39318.1; -;
 KM Hypothetical protein.
 SQ SEQUENCE 96 AA; 10672 MW; 675945A1C87DA30 CRC64;

Query Match 25.8%; Score 51; DB 6; Length 96;
 Best Local Similarity 41.7%; Pred. No. 9;
 Matches 10; Conservative 3; Mismatches 11; Indels 0; Gaps 0;

Qy 10 RDSRPLMKGPALKMKGEAVI 33
 Db 49 RRSSTPHWQSAHPLMSPGLVLT 72

RESULT 7
 Q97KS3 PRELIMINARY; PRT; 91 AA.
 AC Q97KS3; 01-OCT-2001 (TREMBlrel. 18, Created)
 DT 01-OCT-2001 (TREMBlrel. 18, Last sequence update)
 DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
 DE Barstar-like protein ribonuclease (barnase) inhibitor.
 GN CAC0844.
 OS Clostridium acetobutylicum.
 OC Bacteria; Firmicutes; Bacillus/Clostridium group; Clostridia;
 OC Clostridiales; Clostridiaceae; Clostridium.
 OX NCBI_TaxID=1488;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ATCC 824 / DSM 792 / VKM B-1787;
 RX MEDLINE=21359325; PubMed=11466286;
 RA Noelling J., Breton G., Omelchenko M.V., Makarova K.S., Zeng Q.,
 RA Gibson R., Lee H.M., Dubois J., Qiu D., Hiti J., Wolf Y.I.,
 RA Tatusov R.L., Sabathe F., Doucette-Stamm L., Soucaille P., Daly M.J.,
 RA Bennett G.N., Koonin E.V., Smith D.R.;
 RT "Genome sequence and comparative analysis of the solvent-producing
 RT bacterium *Clostridium acetobutylicum*";
 RL J. Bacteriol. 183:4823-4838(2001).
 DR EMBL; AE007600; AAK78820.1; -;
 DR InterPro; IPR000468; Barstar.
 DR Pfam; PF01337; Barstar; 1.
 DR Prodom; PD029050; Barstar; 1.
 KM Complete proteome.
 SQ SEQUENCE 91 AA; 10821 MW; AD4B022BC9FCCBBE CRC64;

Query Match 25.5%; Score 50.5; DB 16; Length 91;
 Best Local Similarity 37.9%; Pred. No. 10;
 Matches 11; Conservative 3; Mismatches 8; Indels 7; Gaps 1;

Qy 5 FRVYRDSRPLMKGEAVI 26
 Db 27 FPYYGKRLDALMDLTGTETPLKIWK 55

RESULT 8
 Q71895 PRELIMINARY; PRT; 44 AA.
 AC Q71895; 01-NOV-1996 (TREMBlrel. 01, Created)
 DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
 DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
 DE Pol protein (Fragment).
 GN POL.
 OS Human immunodeficiency virus type 1.
 OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
 OX NCBI_TaxID=11676;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=CNTRL 1;
 RX MEDLINE=95287475; PubMed=7769682;
 RA Michael N.L., Chang G., d'Arcy L.A., Ehrenberg P.K., Mariani R.,
 RA Busch M.P., Bix D.L., Schwartz D.H.;
 RT "Defective accessory genes in a human immunodeficiency virus type 1-
 RT infected long-term survivor lacking recoverable virus";
 RL J. Virol. 69:4228-4236(1995).
 DR EMBL; U24447; AAA79545.1; -;
 DR InterPro; IPR001037; Integrase_C.
 DR Pfam; PF00552; Integrase; 1.
 FT NON_TER 1
 SQ SEQUENCE 44 AA; 4875 MW; 01901EA27AFA3CDE CRC64;

Query Match 25.3%; Score 50; DB 15; Length 44;

Best Local Similarity 100.0%; Pred. No. 5.3;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 27 GEGAVI0DN 36
1 GEGAVI0DN 10

RESULT 9

ID 071902 PRELIMINARY; PRT; 44 AA.
AC 071902;
DT 01-NOV-1996 (TREMBlrel. 01, Created)
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
DE 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
GN POL.
OS Human immunodeficiency virus type 1.
OC Viruses; Retrovird viruses; Retroviridae; Lentivirus.
OX NCBI_Taxid=11676;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CNTRL.1;
RX MEDLINE=95287475; PubMed=7769682;
RA Michael N.L., Chang G., d'Arcy L.A., Ehrenberg P.K., Mariani R.,
RT "Defective accessory genes in a human immunodeficiency virus type 1-
infected long-term survivor lacking recoverable virus."
RL J. Virol. 69:4228-4236(1995).
DR EMBL; U24449; AAA79552.1;
DR InterPro; IPR001037; Integrase_C.
DR Pfam; PF00552; Integrase; 1.
FT NON TER
SQ SEQUENCE 44 AA; 4875 MW; 01901EA27AAF3CDE CRC64;

Query Match 25.3%; Score 50; DB 15; Length 44;
Best Local Similarity 100.0%; Pred. No. 5.3;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 27 GEGAVI0DN 36
1 GEGAVI0DN 10

RESULT 10

ID 071909 PRELIMINARY; PRT; 44 AA.
AC 071909;
DT 01-NOV-1996 (TREMBlrel. 01, Created)
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
DE 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
GN POL.
OS Human immunodeficiency virus type 1.
OC Viruses; Retrovird viruses; Retroviridae; Lentivirus.
OX NCBI_Taxid=11676;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CNTRL.1;
RX MEDLINE=95287475; PubMed=7769682;
RA Michael N.L., Chang G., d'Arcy L.A., Ehrenberg P.K., Mariani R.,
RT "Defective accessory genes in a human immunodeficiency virus type 1-
infected long-term survivor lacking recoverable virus."
RL J. Virol. 69:4228-4236(1995).
DR EMBL; U24449; AAA79552.1;
DR InterPro; IPR001037; Integrase_C.
DR Pfam; PF00552; Integrase; 1.
FT NON TER
SQ SEQUENCE 44 AA; 4875 MW; 01901EA27AAF3CDE CRC64;

Query Match 25.3%; Score 50; DB 15; Length 44;
Best Local Similarity 100.0%; Pred. No. 5.3;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 27 GEGAVI0DN 36
1 GEGAVI0DN 10

RESULT 11

ID 071916 PRELIMINARY; PRT; 44 AA.
AC 071916;
DT 01-NOV-1996 (TREMBlrel. 01, Created)
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
DE 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
GN POL.
OS Human immunodeficiency virus type 1.
OC Viruses; Retrovird viruses; Retroviridae; Lentivirus.
OX NCBI_Taxid=11676;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CNTRL.1;
RX MEDLINE=95287475; PubMed=7769682;
RA Michael N.L., Chang G., d'Arcy L.A., Ehrenberg P.K., Mariani R.,
RT "Defective accessory genes in a human immunodeficiency virus type 1-
infected long-term survivor lacking recoverable virus."
RL J. Virol. 69:4228-4236(1995).
DR EMBL; U24450; AAA79566.1;
DR InterPro; IPR001037; Integrase_C.
DR Pfam; PF00552; Integrase; 1.
FT NON TER
SQ SEQUENCE 44 AA; 4875 MW; 01901EA27AAF3CDE CRC64;

Query Match 25.3%; Score 50; DB 15; Length 44;
Best Local Similarity 100.0%; Pred. No. 5.3;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 27 GEGAVI0DN 36
1 GEGAVI0DN 10

RESULT 12

ID 071923 PRELIMINARY; PRT; 44 AA.
AC 071923;
DT 01-NOV-1996 (TREMBlrel. 01, Created)
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
DE 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
GN POL.
OS Human immunodeficiency virus type 1.
OC Viruses; Retrovird viruses; Retroviridae; Lentivirus.
OX NCBI_Taxid=11676;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CNTRL.1;
RX MEDLINE=95287475; PubMed=7769682;
RA Michael N.L., Chang G., d'Arcy L.A., Ehrenberg P.K., Mariani R.,
RT "Defective accessory genes in a human immunodeficiency virus type 1-
infected long-term survivor lacking recoverable virus."
RL J. Virol. 69:4228-4236(1995).
DR EMBL; U24451; AAA79573.1;
DR InterPro; IPR001037; Integrase_C.
DR Pfam; PF00552; Integrase; 1.
FT NON TER
SQ SEQUENCE 44 AA; 4875 MW; 01901EA27AAF3CDE CRC64;

Query Match 25.3%; Score 50; DB 15; Length 44;
Best Local Similarity 100.0%; Pred. No. 5.3;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 27 GEGAVVIODN 36
|||||
Db 1 GEGAVVIODN 10

RESULT 13

Q71929 PRELIMINARY; PRT; 44 AA.
ID 071929
AC 071929
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Pol protein (Fragment).
GN POL.
OS Human immunodeficiency virus type 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CNTRL.1;
RX MEDLINE=95287475; PubMed=7769682;
RA Michael N.L., Chang G., d'Arcy L.A., Ehrenberg P.K., Mariani R.,
RA Busch M.P., Birx D.L., Schwartz D.H.;
RT "Defective accessory genes in a human immunodeficiency virus type 1-
RT infected long-term survivor lacking recoverable virus.";
RL J. Virol. 69:4228-4236(1995).
DR EMBL: U24452; AAA79579.1;
DR InterPro: IPR001037; Integrase_C.
DR Pfam: PF00552; Integrase; 1.
FT NON TER 1
SQ SEQUENCE 44 AA; 4875 MW; 01901EA27AFA3CDE CRC64;

Query Match 25.3%; Score 50; DB 15; Length 44;
Best Local Similarity 100.0%; Pred. No. 5.3;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 27 GEGAVVIODN 36
|||||
Db 1 GEGAVVIODN 10

RESULT 14

Q71936 PRELIMINARY; PRT; 44 AA.
ID 071936
AC 071936
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Pol protein (Fragment).
GN POL.
OS Human immunodeficiency virus type 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CNTRL.2;
RX MEDLINE=95287475; PubMed=7769682;
RA Michael N.L., Chang G., d'Arcy L.A., Ehrenberg P.K., Mariani R.,
RA Busch M.P., Birx D.L., Schwartz D.H.;
RT "Defective accessory genes in a human immunodeficiency virus type 1-
RT infected long-term survivor lacking recoverable virus.";
RL J. Virol. 69:4228-4236(1995).
DR EMBL: U24453; AAA79586.1;
DR InterPro: IPR001037; Integrase_C.
DR Pfam: PF00552; Integrase; 1.
FT NON TER 1
SQ SEQUENCE 44 AA; 4690 MW; F0F71C7266DF3CC6 CRC64;

Query Match 25.3%; Score 50; DB 15; Length 44;
Best Local Similarity 100.0%; Pred. No. 5.3;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 27 GEGAVVIODN 36
|||||
Db 1 GEGAVVIODN 10

RESULT 15

Q71942 PRELIMINARY; PRT; 44 AA.
ID 071942
AC 071942
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Pol protein (Fragment).
GN POL.
OS Human immunodeficiency virus type 1.
OC Viruses; Retroid viruses; Retroviridae; Lentivirus.
OX NCBI_TaxID=11676;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CNTRL.2;
RX MEDLINE=95287475; PubMed=7769682;
RA Michael N.L., Chang G., d'Arcy L.A., Ehrenberg P.K., Mariani R.,
RA Busch M.P., Birx D.L., Schwartz D.H.;
RT "Defective accessory genes in a human immunodeficiency virus type 1-
RT infected long-term survivor lacking recoverable virus.";
RL J. Virol. 69:4228-4236(1995).
DR EMBL: U24454; AAA79592.1;
DR InterPro: IPR001037; Integrase_C.
DR Pfam: PF00552; Integrase; 1.
FT NON TER 1
SQ SEQUENCE 44 AA; 4762 MW; F15C041266DF3CC6 CRC64;

Query Match 25.3%; Score 50; DB 15; Length 44;
Best Local Similarity 100.0%; Pred. No. 5.3;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 27 GEGAVVIODN 36
|||||
Db 1 GEGAVVIODN 10

Search completed: May 6, 2003, 14:58:17
Job time : 31 secs


```

GN 3.
OS Mycobacteriophage D29.
OC Viruses: dsDNA viruses, no RNA stage; Caudovirales; Siphoviridae;
OC Unclassified Siphoviridae.
OX NCBI_TaxID=28369.
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=9830035; PubMed=9636706.
RA Ford M.E., Sarkis G.J., Balanger A.E., Hendrix R.W., Hatfull G.F.;
RT "Genome structure of mycobacteriophage D29: implications for phage
RL J. Mol. Biol. 279:143-164(1998).
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
DR EMBL AF022214; AAC18446.1;
SQ SEQUENCE 83 AA; 8962 MW; 2B3D070B4C6F4E09 CRC64;

Query Match
Best Local Similarity 19.2%; Score 38; DB 1; Length 83;
Matches 7; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

OY 17 WKGPRLMKRGAGAVI00 35
DB 42 WEGLEILEYSGDQVEVSD 60

RESULT 3
GGBB HUMAN
AC P50152; STANDARD; PRT; 73 AA.
DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DB Gnanine nucleotide-binding protein G(i1)/G(s)/G(o) gamma-11 subunit.
GN GNG11 OR GNG11.
OS Homo sapiens (Human).
OS Mus musculus (Mouse), and
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606, 10090, 10116;
RN [1]
RP SEQUENCE FROM N.A., AND ISOPRENOID.
RX SPECIES=Human; TISSUE=Testis;
RA MEDLINE=95394940; PubMed=765396;
RA Ray K., Kunsch C., Bonner L.M., Robishaw J.D.;
RT "Isolation of cDNA clones encoding eight different human G protein
RT gamma subunits, including three novel forms designated the gamma 4,
RL gamma 10, and gamma 11 subunits.";
RN J. Biol. Chem. 270:21765-21771(1995).
RN [2]
RP SEQUENCE FROM N.A.
RX SPECIES=Human;
RA Maggi L.;
RL Submitted (MAY-1997) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RX SPECIES=Human; TISSUE=Lung;
RA Strauberg R.;
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RX SPECIES=Mouse; STRAIN=C57BL/6J; TISSUE=Kidney, and Tongue;
RA MEDLINE=1085660; PubMed=11217851;
RA Kawai J., Shingawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Atakawa T., Hara A., Fukunishi Y., Kono H., Adachi J., Fukuda S.,

```

```

RA Alizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gotohori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batilov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochava H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schirml L.M., Staubl F., Suzuki R., Tonit M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bull C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whitaker X., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohlski S.,
RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
RN [5]
RP SEQUENCE FROM N.A.
RX SPECIES=Rat; STRAIN=Sprague-Dawley;
RA Costain W.J., Mishra R.K.;
RT "Identification and cloning of rat G protein gamma 11 subunit.";
RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: GUANINE NUCLEOTIDE-BINDING PROTEINS (G PROTEINS) ARE
CC INVOLVED AS A MODULATOR OR TRANSDUCER IN VARIOUS TRANSMEMBRANE
CC SIGNALING SYSTEMS. THE BETA AND GAMMA CHAINS ARE REQUIRED FOR THE
CC GTPASE ACTIVITY, FOR REPLACEMENT OF GDP BY GTP, AND FOR G PROTEIN-
CC RECEPTOR INTERACTION. INTERACTS WITH BETA-1 AND BETA-3, BUT NOT
CC WITH BETA-2.
CC -1- SUBUNIT: G PROTEINS ARE COMPOSED OF 3 UNITS (ALPHA, BETA & GAMMA).
CC -1- TISSUE SPECIFICITY: ABUNDANTLY EXPRESSED IN ALL TISSUES TESTED
CC EXCEPT FOR BRAIN.
CC -1- SIMILARITY: BELONGS TO THE G PROTEIN GAMMA FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
DR EMBL, U31384; AAC50206.1;
DR EMBL, AC002076; AAB54051.1;
DR EMBL, BC009709; AAB09709.1;
DR EMBL, AK002765; BAB2340.1;
DR EMBL, AK009529; BAB26342.1;
DR EMBL, AF257110; AAF68984.1;
DR HSSP; P02698; 189X.
DR GeneW; HGNC:4403; GNG11.
DR MIM; 604390;
DR InterPro; IPR001770; G-gamma.
DR InterPro; IPR001230; Prenyl_site.
DR Pfam; PF00631; G-gamma.1.
DR PRINTS; PR00321; GPROTEING.
DR PRODOM; PD003763; G-gamma; 1.
DR SMART; SM00224; GGL; 1.
DR PROSITE; PS50058; G_PROTEIN_GAMMA.1.
DR Transducer; Prenylation; Lipoprotein; Multigene family.
FT LIPID 70
FT LIPID 70
FT PROPSP 71
FT PROPSP 73
SQ SEQUENCE 73 AA; 8481 MW; 2B13935E3AEFB9E8 CRC64;

Query Match
Best Local Similarity 18.9%; Score 37.5; DB 1; Length 73;
Matches 13; Conservative 7; Mismatches 12; Indels 3; Gaps 2;

OY 1 KIONPYYVRSDRLPMG--PAKLTKGEGAVI 33
DB 39 EIKNY-IEBSGEDEPLVGIPEDKNPFKEKSCVI 72

```

```
RESULT 4
ID IF1A_ARCFU STANDARD; PRT; 97 AA.
AC 029481;
DT 15-JUL-1998 (Rel. 36, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-JUN-2002 (Rel. 41, Last annotation update)
DE Probable translation initiation factor 1A (aIF-1A).
GN aIF1A OR AF0777.
OS Archaeoglobus fulgidus.
OC Archaea; Euryarchaeota; Archaeoglobi; Archaeoglobales;
OC Archaeoglobaceae; Archaeoglobus.
OX NCBI_TaxID=2234;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=VC-16 / DSM 4304 / ATCC 49558;
RX MEDLINE=98049343; PubMed=9389475;
RA Kleink H.-P., Clayton R.A., Tomb J.-F., White O., Nelson K.E.,
RA Ketchum K.A., Dodson R.J., Gwinn M., Hickey E.K., Peterson J.D.,
RA Richardson D.L., Kervilange A.R., Graham D.E., Kyriades N.C.,
RA Fleischmann R.D., Quackenbush J., Lee N.H., Sutton G.G., Gill S.,
RA Kirkness E.F., Dougherty B.A., McKenney K., Adams M.D., Loftus B.,
RA Peterson S., Reich C.I., McNeil L.K., Badger J.H., Glodek A., Zhou L.,
RA Overbeek R., Gocayne J.D., Weidman J.F., McDonald L., Uterback T.,
RA Cotton M.D., Spriggs T., Artlich P., Kaine B.P., Sykes S.M.,
RA Sadow P.W., D'Andrea K.P., Bowman C., Fujii C., Garland S.A.,
RA Mason T.M., Olsen G.J., Fraser C.M., Smith H.O., Woese C.R.,
RA Venter J.C.;
RT "The complete genome sequence of the hyperthermophilic, sulphate-
RT reducing archaeon Archaeoglobus fulgidus."
RL Nature 390:364-370(1997).
CC -1- FUNCTION: Seems to be required for maximal rate of protein
CC biosynthesis. Enhances ribosome dissociation into subunits and
CC stabilizes the binding of the initiator Met-tRNA(I) to 40 S
CC ribosomal subunits (By similarity).
CC -1- SIMILARITY: BELONGS TO THE EIF-1A FAMILY.
CC -1- SIMILARITY: CONTAINS 1 SL-LIKE DOMAIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AE001051; AAB90469.1; ALT_INIT.
DR TIGR; AF0777; -.
DR InterPro; IPR001253; TIF_eIF-1A.
DR Pfam; PF01176; eIF-1a; 1.
DR ProDom; PD005579; TIF_eIF-1A; 1.
DR TIGRFAMs; TIGR00523; eIF-1A; 1.
DR PROSITE; PS01262; IF1A; 1.
DR PROSITE; PS50832; SL_IP1_TYPE; 1.
KM Initiation factor; Protein biosynthesis; Complete proteome.
FT DOMAIN 8 82 SL-LIKE.
SQ SEQUENCE 97 AA; 11385 MW; 12332D5E9CB82DA1 CRC64;

Query Match 18.4%; Score 36.5; DB 1; Length 97;
Best Local Similarity 33.3%; Pred. No. 2.2e+02;
Matches 11; Conservative 6; Mismatches 13; Indels 3; Gaps 1;
```

```
RESULT 5
ID YG50_HABIN STANDARD; PRT; 36 AA.
AC P44281;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)

Query Match 18.2%; Score 36; DB 1; Length 36;
Best Local Similarity 42.9%; Pred. No. 90;
Matches 9; Conservative 2; Mismatches 8; Indels 2; Gaps 1;

RESULT 6
ID GBG1_BOVIN STANDARD; PRT; 73 AA.
AC P02698;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Guanine nucleotide-binding protein G(T) gamma-T1 subunit (Transducin
DE gamma chain).
GN GNCT1.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=85063709; PubMed=6438626;
RA Hurley J.B., Fong H.K.W., Teplow D.B., Dreyer W.J., Simon M.I.,
RT "Isolation and characterization of a cDNA clone for the gamma subunit
RT of bovine retinal transducin."
RL Proc. Natl. Acad. Sci. U.S.A. 81:6948-6952(1984).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=85166247; PubMed=2984674;
RA Yatsunami K., Pandya B.V., Orian D.D., Khorana H.G.;
RT "cDNA-derived amino acid sequence of the gamma subunit of GTPase from
```

RT bovine rod outer segments.";
 RL Proc. Natl. Acad. Sci. U.S.A. 82:1936-1940(1985).
 RN [3]
 RP SEQUENCE FROM N.A.
 RA MEDLINE=93272877; PubMed=8500562;
 RT Tao L., Pandey S., Simon M.I., Fong H.K.;
 RT "Structure of the bovine transducin gamma subunit gene and analysis
 RL Exp. Eye Res. 56:497-507(1993).
 RN [4]
 RP SEQUENCE OF 1-39 FROM N.A.
 RA MEDLINE=85046503; PubMed=6149748;
 RT van Dorp C., Medynski D.C., Sullivan K., Wu A.M., Fung B.K.-K.,
 RT Bourne H.R.;
 RL "Partial cDNA sequence of the gamma subunit of transducin.";
 RN Biochem. Biophys. Res. Commun. 124:250-255(1984).
 RP [5]
 RA SEQUENCE OF 1-69.
 RA MEDLINE=85076983; PubMed=3917402;
 RA Ovchinnikov Y.A., Lipkin V.M., Shvavaya T.M., Bogachuk A.P.,
 RA Shemyakin V.V.;
 RT "Complete amino acid sequence of gamma-subunit of the GTP-binding
 RT protein from cattle retina.";
 RL FEBS Lett. 179:107-110(1985).
 RN [6]
 RP ISOPRENOID.
 RA MEDLINE=90348966; PubMed=2385292;
 RA Fukuda Y., Takao T., Ohguro H., Yoshizawa T., Akiho T.,
 RA Shimomishi Y.;
 RT "Farnesylated gamma-subunit of photoreceptor G protein indispensable
 RT for GTP-binding.";
 RL Nature 346:658-660(1990).
 RN [7]
 RP ISOPRENOID.
 RA MEDLINE=91236727; PubMed=1903391;
 RA Sanford J., Codina J., Birnbaumer L.;
 RT "Gamma-subunits of G proteins, but not their alpha- or beta-subunits,
 RT are polyisoprenylated. Studies on post-translational modifications
 RT using in vitro translation with rabbit reticulocyte lysates.";
 RL J. Biol. Chem. 266:9570-9579(1991).
 RN [8]
 RP ISOPRENOID.
 RA MEDLINE=91017567; PubMed=2217200;
 RA Lai R.K., Perez-Sala D., Canada F.J., Rando R.R.;
 RT "The gamma subunit of transducin is farnesylated.";
 RL Proc. Natl. Acad. Sci. U.S.A. 87:7673-7677(1990).
 RN [9]
 RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF BETA-GAMMA DIMER.
 RA MEDLINE=9619254; PubMed=8552196;
 RA Sonder J., Both A., Lambright D.G., Hamm H.E., Sigler P.B.;
 RT "Crystal structure of a G-protein beta gamma dimer at 2.1-A
 RT resolution.";
 RL Nature 379:369-374(1996).
 RN [10]
 RP X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF COMPLEX WITH PHOSUDCIN.
 RA MEDLINE=98416696; PubMed=9739091;
 RA Loew A., Ho Y.K., Blundell T., Bax B.;
 RT "Phosudcin induces a structural change in transducin beta gamma.";
 RL Structure 6:1007-1019(1998).
 RN [11]
 RP FUNCTION: GUANINE NUCLEOTIDE-BINDING PROTEINS (G PROTEINS) ARE
 RP INVOLVED AS A MODULATOR OR TRANSDUCER IN VARIOUS TRANSMEMBRANE
 RP SIGNALING SYSTEMS. THE BETA AND GAMMA CHAINS ARE REQUIRED FOR THE
 RP EFFECTOR INTERACTION.
 RP -1- SUBUNIT: G PROTEINS ARE COMPOSED OF 3 UNITS (ALPHA, BETA & GAMMA).
 RP -1- TISSUE SPECIFICITY: RETINAL ROD OUTER SEGMENT.
 RP -1- SIMILARITY: BELONGS TO THE G PROTEIN GAMMA FAMILY.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial

CC entries requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: K03255; AAA0794.1; -
 DR EMBL: K02199; AAA0793.1; -
 DR EMBL: S62031; AAB26895.1; -
 DR EMBL: S62029; AAB26895.1; JOINED.
 DR EMBL: K02436; AAA0788.1; -
 DR PIR: A03153; RQBQGT
 DR PDB: 1TRG; 01-APR-97.
 DR PDB: 1AOR; 16-FEB-99.
 DR PDB: 1B9X; 23-FEB-99.
 DR PDB: 1B9Y; 23-FEB-99.
 DR InterPro: IPR001770; G-gamma.
 DR InterPro: IPR001230; Prenyl_site.
 DR Pfam: PF00631; G-gamma; 1.
 DR PRINTS: PR00321; GPROTEIN.
 DR ProDom: PD003783; G-gamma; 1.
 DR SMART: SM00224; GGL; 1.
 DR PROSITE: PS50058; G-PROTEIN GAMMA; 1.
 KW Transducer; Prenylation; Lipoprotein; Multigene family; 3D-structure.
 FT INIT MET 0 0
 FT DISULFID 35 36 FARNESYL.
 FT LIPID 70 70 REMOVED IN MATURE FORM.
 FT PROPEP 71 73 B1743B36F4BD2505 CRC64;
 SQ SEQUENCE 73 AA; 8413 MW; 81743B36F4BD2505 CRC64;
 Query Match 18.2%; Score 36; DB 1; Length 73;
 Best local similarity 42.1%; Pred. No. 1.9e+02;
 Matches 16; Conservative 2; Mismatches 10; Indels 10; Gaps 4;
 Oy 3 QNFRVYV--RDSRPLMKG-----PAKLWKGGAHV 32
 Db 37 EEFRDYVERSGEDPLVKGIPEDKXPFKL-KG-GCVI 72
 RESULT 7
 R35A_PYRAB
 ID R35A_PYRAB STANDARD; PRT; 87 AA.
 AC Q9V1P2;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE 50S ribosomal protein L35ae.
 GN RPL35AE OR PAB7092.
 OS Pyrococcus abyssi.
 OC Archaea; Buryarchaeota; Thermococci; Thermococcales; Thermococcaceae;
 OC NCBI_TaxID=29292;
 RN NCBI_TaxID=29292;
 RP [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=GES / Orsay;
 RA Heilig R.;
 RT "Pyrococcus abyssi genome sequence: insights into archaeal chromosome
 RT structure and evolution.";
 RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.
 RN [12]
 RP -1- SIMILARITY: BELONGS TO THE L35AE FAMILY OF RIBOSOMAL PROTEINS.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entries requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: AJ248284; CAB49307.1; -
 DR InterPro: IPR001780; Ribosomal_L35AE.
 DR Pfam: PF01247; Ribosomal_L35AE; 1.
 DR ProDom: PD012670; Ribosomal_L35AE; 1.
 DR PROSITE: PS01105; RIBOSOMAL_L35AE; 1.
 KW Ribosomal protein; Complete proteome.
 SQ SEQUENCE 87 AA; 9736 MW; 79A625A3AF74958 CRC64;

Query Match 18.2%; Score 36; DB 1; Length 87;
 Best Local Similarity 46.2%; Pred. No. 2.3e+02;
 Matches 6; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Oy 16 LMKGPAKLKMG 28
 Db 44 LMKSPGKILKMG 56

RESULT 8

R35A_PYRPU STANDARD; PRT; 87 AA.
 ID R35A_PYRPU
 AC Q8T2V6;
 DT 15-JUN-2002 (Rel. 41, Created)
 DT 15-JUN-2002 (Rel. 41, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE 508 ribosomal protein L35Ae.
 GN RPL35AE OR P1872.
 OS Pyrococcus furiosus.
 OC Archaea; Euryarchaeota; Thermococci; Thermococcales; Thermococcaceae;
 CC Pyrococcus.
 OX NCBI_TaxID=2261;
 RN [1]
 RP SEQUENCE FROM N.A.

RC STRAIN=Vci / DSM 3638 / ATCC 43587 / JCM 8422;
 RA Weiss R.B., Dunn D.M., Robb F.T., Brown J.R.;
 RT "The complete sequence of the Pyrococcus furiosus genome."
 RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
 CC -1- SIMILARITY: BELONGS TO THE L35AE FAMILY OF RIBOSOMAL PROTEINS.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; AE010282; AAL81996.1;
 DR InterPro; IPR001780; Ribosomal_L35AE.
 DR Pfam; PF01247; Ribosomal_L35AE; 1.
 DR ProDom; PD012670; Ribosomal_L35AE; 1.
 DR PROSITE; PS01105; RIBOSOMAL_L35AE; 1.
 KW Ribosomal protein; Complete proteome.
 SQ SEQUENCE 87 AA; 9735 MW; FSC425AA3A09247 CRC64;

Query Match 18.2%; Score 36; DB 1; Length 87;
 Best Local Similarity 46.2%; Pred. No. 2.3e+02;
 Matches 6; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Oy 16 LMKGPAKLKMG 28
 Db 44 LMKSPGKILKMG 56

RESULT 9

R35A_PYRWO STANDARD; PRT; 87 AA.
 ID R35A_PYRWO
 AC P20299;
 DT 01-FEB-1991 (Rel. 17, Created)
 DT 01-FEB-1991 (Rel. 17, Last sequence update)
 DT 30-MAY-2000 (Rel. 39, Last annotation update)
 DE 508 ribosomal protein L35Ae.
 GN RPL35AE.
 OS Pyrococcus woesei.
 OC Archaea; Euryarchaeota; Thermococci; Thermococcales; Thermococcaceae;
 CC Pyrococcus.
 OX NCBI_TaxID=2262;
 RN [1]
 RP SEQUENCE FROM N.A.

RC STRAIN=DSM 3773;
 MEDLINE=90330536; PubMed=2165475;
 RX

RA Zwickl P., Fabry S., Bogedain C., Haas A., Hensel R.;
 RT "Glyceradehyde-3-phosphate dehydrogenase from the hyperthermophilic
 RT archaeobacterium Pyrococcus woesei: characterization of the enzyme,
 RT cloning and sequencing of the gene, and expression in Escherichia
 RT coli."

RL J. Bacteriol. 172:4329-4338(1990).
 CC -1- SIMILARITY: BELONGS TO THE L35AE FAMILY OF RIBOSOMAL PROTEINS.
 DR PIR; S10651; OOOYVW.
 DR InterPro; IPR001780; Ribosomal_L35AE.
 DR Pfam; PF01247; Ribosomal_L35AE; 1.
 DR ProDom; PD012670; Ribosomal_L35AE; 1.
 DR PROSITE; PS01105; RIBOSOMAL_L35AE; 1.
 KW Ribosomal protein.
 SQ SEQUENCE 87 AA; 9666 MW; B5D524BBA3A148EC CRC64;

Query Match 18.2%; Score 36; DB 1; Length 87;
 Best Local Similarity 46.2%; Pred. No. 2.3e+02;
 Matches 6; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Oy 16 LMKGPAKLKMG 28
 Db 44 LMKSPGKILKMG 56

RESULT 10

YVAP_VACCC STANDARD; PRT; 89 AA.
 ID YVAP_VACCC
 AC P20525;
 DT 01-FEB-1991 (Rel. 17, Created)
 DT 01-FEB-1991 (Rel. 17, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Hydrophobic 9.9 kDa protein.

GN A ORF P. P. Vaccinia virus (strain Copenhagen).
 OS Vaccinia virus (strain Copenhagen).
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 CC Orthopoxvirus.
 OX NCBI_TaxID=10249;
 RN [1]
 RP SEQUENCE FROM N.A.

RX MEDLINE=91021027; PubMed=2219722;
 RA Goebel S.J., Johnson G.P., Perkins M.E., Davis S.W., Winslow J.P.,
 RA Paoletti E.;
 RT "The complete DNA sequence of vaccinia virus."
 RL Virology 179:247-266(1990).
 RN [2]
 RP COMPLETE GENOME.

RA Goebel S.J., Johnson G.P., Perkins M.E., Davis S.W., Winslow J.P.,
 RA Paoletti E.;
 RT "Appendix to 'The complete DNA sequence of vaccinia virus'."
 RL Virology 179:517-563(1990).

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

DR EMBL; M35027; AAA48170.1;
 DR PIR; C42525; C42525.
 KW Hypothetical protein.
 SQ SEQUENCE 89 AA; 9909 MW; 399EA9270DF3E75A CRC64;

Query Match 18.2%; Score 36; DB 1; Length 89;
 Best Local Similarity 35.7%; Pred. No. 2.4e+02;
 Matches 5; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

Oy 19 GPAKLKMGAGAV 32
 Db 24 GPSKIGWLKGFII 37

PDB; 1B2U; 09-DEC-98.

Db 29 YGGENLDALWDCLTGWEYPLVEWR 54

Matches	Conservative	Mismatches	Indels	Gaps
7	3	5	7	1

Qy 15 PLMKGPATLWKGGAVVIOFN 36
Db 57 PSW-----WESSGRVVEYN 71

RESULT 13

A4 MACMU STANDARD; PRT; 76 AA.

AC P29216;

DT 01-DEC-1992 (Rel. 24, Created)

DT 01-DEC-1992 (Rel. 24, Last sequence update)

DT 16-OCT-2001 (Rel. 40, Last annotation update)

DE Alzheimer's disease amyloid A4 protein (Fragment).

GN APP.

OS Macaca mulatta (Rhesus macaque).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;

OC Cercopithecoidea; Macaca.

OX NCBI_TaxID=9544;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Brain;

RA Koo E.H., Sisodia S.S., Price D.L.;

RL Submitted (JUL-1989) to the EMBL/GenBank/DBJ databases.

CC -1- FUNCTION: FUNCTIONAL NEURONAL RECEPTOR WHICH COUPLES TO

CC INTRACELLULAR SIGNALING PATHWAY THROUGH THE GTP-BINDING PROTEIN

CC G(O) (BY SIMILARITY).

CC -1- SUBCELLULAR LOCATION: Type I membrane protein.

CC -1- ALTERNATIVE PRODUCTS: 5 ISOFORMS; APP(395), APP(563), APP(695),

CC APP(751) AND APP(770) (SHOWN HERE); ARE PRODUCED BY ALTERNATIVE

CC SPLICING (BY SIMILARITY).

CC -1- SIMILARITY: BELONGS TO THE APP FAMILY.

CC -1- SIMILARITY: CONTAINS 1 BPTI/KUNITZ INHIBITOR DOMAIN.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@isb-sib.ch).

CC -----

DR EMBL: X15985; CAA34116.1; -

DR PIR: S06678; S06678.

DR HSP; P05067; 1AAP.

DR InterPro: IPR001868; A4_APP.

DR InterPro: IPR002223; Kunitz_BPTI.

DR Pfam: PFO0014; Kunitz_BPTI_1.

DR PRODOM: PD000222; Kunitz_BPTI_1.

DR SMART: SM00131; KU_1.

DR PROSITE: PS00319; A4_EXTRA; PARTIAL.

DR PROSITE: PS00320; A4_INTRA; PARTIAL.

DR PROSITE: PS00280; BPTI_KUNITZ_1; 1.

DR PROSITE: PS50279; BPTI_KUNITZ_2; 1.

KW Glycoprotein; Amyloid; Neurone; Alternative splicing;

KW Serine protease inhibitor.

FT NON_TER 1 1

FT DOMAIN 1 76 BPTI/KUNITZ INHIBITOR.

FT ACT_SITE 13 14 REACTIVE BOND.

FT DISULFID 3 53 BY SIMILARITY.

FT DISULFID 12 36 BY SIMILARITY.

FT DISULFID 28 49 BY SIMILARITY.

FT NON_TER 76 76

SEQUENCE 76 AA; 8527 MW; 492BPF3069AB082A1 CRC64;

Query Match 17.7%; Score 35; DB 1; Length 76;

Best Local Similarity 42.9%; Pred. No. 2.8e+02;

Matches 6; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 10 RDSRDLPLWKGPATL 23

Db 63 KTRRPLTRDRPVKL 76

RESULT 14
VG7_SPVIR STANDARD; PRT; 83 AA.

AC P15898;

DT 01-APR-1990 (Rel. 14, Created)

DT 01-FEB-1996 (Rel. 33, Last sequence update)

DT 01-FEB-1996 (Rel. 33, Last annotation update)

DE Gene 7 protein.

GN 7.

OS Spiroplasma virus SpV1-R8A2 B.

OC Viruses; ssDNA viruses; Inoviridae; Plectrovirus.

OX NCBI_TaxID=10854;

RN [1]

RP SEQUENCE FROM N.A.

RA MEDLINE=90206799; Pubmed=2320423;

RA Renaudin J., Aulio P., Vignault J.C., Bove J.M.;

RT "Complete nucleotide sequence of the genome of Spiroplasma citri

RT virus SpV1-R8A2 B.";

RL Nucleic Acids Res. 18:1293-1293(1990).

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@isb-sib.ch).

CC -----

DR EMBL: X51344; CAA35731.1; -

DR PIR: S31018; S31018.

DR HSP; P05067; 1AAP.

DR InterPro: IPR001868; A4_APP.

DR InterPro: IPR002223; Kunitz_BPTI.

DR Pfam: PFO0014; Kunitz_BPTI_1.

DR PRODOM: PD000222; Kunitz_BPTI_1.

DR SMART: SM00131; KU_1.

DR PROSITE: PS00319; A4_EXTRA; PARTIAL.

DR PROSITE: PS00320; A4_INTRA; PARTIAL.

DR PROSITE: PS00280; BPTI_KUNITZ_1; 1.

DR PROSITE: PS50279; BPTI_KUNITZ_2; 1.

KW Glycoprotein; Amyloid; Neurone; Alternative splicing;

KW Serine protease inhibitor.

FT NON_TER 1 1

FT DOMAIN 1 76 BPTI/KUNITZ INHIBITOR.

FT ACT_SITE 13 14 REACTIVE BOND.

FT DISULFID 3 53 BY SIMILARITY.

FT DISULFID 12 36 BY SIMILARITY.

FT DISULFID 28 49 BY SIMILARITY.

FT NON_TER 76 76

SEQUENCE 76 AA; 8527 MW; 492BPF3069AB082A1 CRC64;

Query Match 17.7%; Score 35; DB 1; Length 83;

Best Local Similarity 45.5%; Pred. No. 3.1e+02;

Matches 5; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 16 LMKGPATLWK 26

Db 28 IWTGUSALWK 38

SQ SEQUENCE 85 AA; 10250 MM; 5032BSA1400FF4A7 CRC64;
 Query Match 17.7%; Score 35; DB 1; Length 85;
 Best Local Similarity 32.4%; Pred. No. 3.2e+02;
 Matches 11; Conservative 4; Mismatches 13; Indels 6; Gaps 2;
 QY 2 IQFRVYRDSRDP LMKGP AKL LMKGGA VV IOD 35
 Db 28 IKDIRKWFRA DHQ-WK-----TWHDPA PFEQD 55

Search completed: May 6, 2003, 14:57:41
 Job time : 12 secs

GenCore version 5.1.4 p5 4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 6, 2003, 14:56:24 ; Search time 16 seconds

(without alignments)
216.302 Million cell updates/sec

Title: US-09-868-399-1

Perfect score: 198
Sequence: 1 KIQNFRYYRSDRDP LMKGPALKLMKGGA VVIQDN 36

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 37666

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

1: PIR.73:*
2: PIR1:*
3: PIR3:*
4: PIR4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	53.5	27.0	70	2	A69842
2	50.5	25.5	91	2	A97004
3	50	25.3	44	2	T09381
4	48.5	24.5	95	2	A81176
5	45	22.7	82	2	B95846
6	42	21.2	76	2	AD2538
7	41.5	21.0	96	2	G83600
8	41	20.7	94	2	A69848
9	40.5	20.5	68	2	AG3217
10	39.5	19.9	63	2	S26796
11	39.5	19.9	87	2	T03193
12	39.5	19.9	88	2	T36458
13	39.5	19.9	96	2	T36605
14	39	19.7	62	2	A12304
15	39	19.7	64	2	T05933
16	39	19.7	79	2	T37100
17	39	19.7	96	2	G64900
18	38.5	19.4	61	2	C75321
19	38.5	19.4	62	2	T26847
20	38.5	19.4	66	2	S32027
21	38.5	19.4	96	2	A71151
22	38.5	19.4	96	2	S75031
23	38	19.2	60	2	H81170
24	38	19.2	81	2	B95286
25	38	19.2	83	2	C72800
26	38	19.2	96	2	H81147
27	38	19.2	100	2	F95369
28	37.5	18.9	60	2	H97179
29	37.5	18.9	67	2	AF1915

30	37.5	18.9	73	2	I39159	GMP-binding regula
31	37.5	18.9	88	2	T17532	hypothetical prote
32	37	18.7	50	2	S68843	sucrose 1P-fructos
33	37	18.7	56	2	B69185	hypothetical prote
34	37	18.7	76	2	B97816	hypothetical prote
35	37	18.7	77	2	A83468	hypothetical prote
36	37	18.7	82	2	H84046	hypothetical prote
37	37	18.7	94	2	H84041	hypothetical prote
38	36.5	18.4	62	2	D69045	hypothetical prote
39	36.5	18.4	88	2	A69347	translation initia
40	36.5	18.4	97	2	E90278	hypothetical prote
41	36.5	18.4	98	2	F90314	hypothetical prote
42	36.5	18.4	99	2	E90338	hypothetical prote
43	36	18.2	36	2	C64039	hypothetical prote
44	36	18.2	46	2	F87527	hypothetical prote
45	36	18.2	52	2	S21185	beta-fructofuranos

ALIGNMENTS

RESULT 1

A69842 hypothetical protein ylix - Bacillus subtilis

C/Species: Bacillus subtilis

C/Date: 05-Dec-1997 #sequence_revision 05-Dec-1997 #text_change 15-Oct-1999

C/Accession: A69842

R/Kunst, F.; Ogasawara, N.; Moszer, I.; Albertini, A.M.; Alloni, G.; Azevedo, V.; Berte

C.; Bron, S.; Brouillet, S.; Bruschi, C.V.; Caldwell, B.; Capuano, V.; Carter, N.M.; Ch

A.; Ehrlich, S.D.; Emerson, P.T.; Entian, K.D.; Errington, J.; Fabret, C.; Ferrari, E.

Nature 390, 249-256, 1997

A/Authors: Foulger, D.; Fritz, C.; Fujita, M.; Fujita, Y.; Fuma, S.; Galizzi, A.; Gall

iech, J.; Harwood, C.R.; Henaut, A.; Hilbert, H.; Holzapfel, S.; Hosono, S.; Hullo, M.F

Koelter, P.; Koningsstein, G.; Krogh, S.; Kumano, M.; Kurita, K.; Lapidus, A.; Lardinois

A/Authors: Lauber, J.; Lazarevic, V.; Lee, S.M.; Levine, A.; Liu, H.; Masuda, S.; Maue

Y, M.; Ogawa, K.; Ogiwara, A.; Oudega, B.; Park, S.H.; Parro, V.; Pohl, T.M.; Portetelli

Rieger, M.; Rivolta, C.; Roche, E.; Roche, B.; Rose, M.; Sadale, Y.; Sato, T.; Scanlon

A/Authors: Schleich, S.; Schroeter, R.; Scoffone, F.; Sekiguchi, J.; Sekowska, A.; Sero

akeuchi, M.; Tamakoshi, A.; Tanaka, T.; Terstra, P.; Tognoni, A.; Tosato, V.; Uchiyama

T.; Winters, P.; Wipat, A.; Yamamoto, H.; Yamane, K.; Yasumoto, K.; Yata, K.; Yoshida,

A/Authors: Yoshikawa, H.F.; Zumbstein, E.; Yoshikawa, H.; Danchin, A.

A/Title: The complete genome sequence of the Gram-positive bacterium Bacillus subtilis.

A/Reference number: A69580; MUID:98044033; PMID:9384377

A/Accession: A69842

A/Status: preliminary; nucleic acid sequence not shown; translation not shown

A/Molecule type: DNA

A/Residues: 1-70 <KUN>

A/Cross-references: GB:299109; GB:AL009126; NID:g2633260; PIDN:CA812957.1; PID:e1183119

A/Experimental source: strain 168

C/Genetics:

A/Gene: ylix

Query Match

Best Local Similarity 27.0%; Score 53.5; DB 2; Length 70;

Matches 12; Conservative 5; Mismatches 10; Indels 1; Gaps 1;

QY 6 RYRDRSDRDP LMKGPALKLMKGGA VVI 33

DB 44 RLYR-RRPCKRTGKXIMWEDAVV 70

RESULT 2

A97004

barstar-like protein ribonuclease (barnase) inhibitor [imported] - Clostridium acetobut

C/Species: Clostridium acetobutylicum

C/Date: 14-Sep-2001 #sequence_revision 14-Sep-2001 #text_change 14-Sep-2001

C/Accession: A97004

R/Neilling, J.; Breton, G.; Omeichenko, M.V.; Markarova, K.S.; Zeng, Q.; Gibson, R.; Lee

; Daly, M.J.; Bennett, G.N.; Koonin, E.V.; Smith, D.R.

J. Bacteriol. 183, 4823-4838, 2001

A/Title: Genome Sequence and Comparative Analysis of the Solvent-Producing Bacterium C1

A/Reference number: A96900; MUID:21359325; PMID:21359325

A/Accession: A97004

A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-91 <KUR>
 A:Cross-references: GB:AE001437; PIDN:AAK78820.1; PID:915023737; GSPDB:GN00168
 A:Experimental source: Clostridium acetobutylicum ATCC824
 C:Genetics:
 A:Gene: CAC0044

Query Match 25.5%; Score 50.5; DB 2; Length 91;
 Best Local Similarity 37.9%; Pred. No. 6.2;
 Matches 11; Conservative 3; Mismatches 8; Indels 7; Gaps 1;

QY 5 FRYYGSDSDPIM-----KGPATLWK 26
 DB 27 FPEYGNLMDLWDLTGTMTKPLKIVK 55

RESULT 3

109381
 pol polyprotein - human immunodeficiency virus type 1 (isolate ctrl 1) (fragment)
 C:Species: human immunodeficiency virus type 1, HIV-1
 A:Variety: isolate ctrl 1
 C>Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 23-Jul-1999
 R:Accession: T09381

R:McMeehl, N.L.; Chang, G.; d'Arcy, L.A.; Ehrenberg, P.K.; Mariani, R.; Busch, M.P.; Bit
 J. Virol. 69, 4228-4236, 1995
 A>Title: Defective accessory genes in a human immunodeficiency virus type 1-infected lo
 A:Reference number: Z16554; MUID:95287475; PMID:7769682
 A:Accession: T09381
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-44 <MTC>
 A:Cross-references: EMBL:U24451; NID:9829440; PID:9829441
 C:Genetics:
 A:Gene: pol
 C:Superfamily: pol polyprotein
 C:Keywords: AIDS; immunodeficiency; polyprotein

Query Match 25.3%; Score 50; DB 2; Length 44;
 Best Local Similarity 100.0%; Pred. No. 3.2;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 27 GEGAVIODN 36
 DB 1 GEGAVIODN 10

RESULT 4

AB1176
 ribonuclease inhibitor baretar NMB0646 [imported] - Neisseria meningitidis (strain MCS8
 C:Species: Neisseria meningitidis
 C>Date: 31-Mar-2000 #sequence_revision 31-Mar-2000 #text_change 19-Jan-2001
 R:Accession: AB1176

R:Teitelin, H.; Saunders, N.J.; Heidelberg, J.; Jeffries, A.C.; Nelson, K.E.; Eisen, J.A
 Hickey, E.K.; Haft, D.H.; Salzberg, S.L.; White, O.; Fleischmann, R.D.; Dougherty, B.A.;
 ri, H.; Qin, H.; Vamathevan, J.; Gill, J.; Scariato, V.; Masiugani, V.; Pizsa, M.
 Science 287, 1809-1815, 2000
 A:Authors: Grandi, G.; Sun, L.; Smith, H.O.; Fraser, C.M.; Moxon, E.R.; Rappunli, R.; Ve
 A>Title: Complete genome sequence of Neisseria meningitidis serogroup B strain MCS8.
 A:Reference number: AB1000; MUID:2017575; PMID:10710307
 A:Accession: AB1176
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-95 <TET>
 A:Cross-references: GB:AE002419; GB:AE002098; NID:97225863; PIDN:AAF1067.1; PID:9722587
 A:Experimental source: serogroup B, strain MCS8
 C:Genetics:
 A:Gene: NMB0646

Query Match 24.5%; Score 48.5; DB 2; Length 95;
 Best Local Similarity 33.3%; Pred. No. 12;
 Matches 11; Conservative 6; Mismatches 9; Indels 7; Gaps 1;

QY 1 KIONFRYYGSDSDPIM-----KGPATLWK 26
 DB 22 KIFSIQDYGNLMDLWDLTSTVERPITLWK 54

RESULT 5

B95846
 hypothetical protein [imported] - Sinorhizobium meliloti (strain 1021) megaplasmid pSym
 C:Species: Sinorhizobium meliloti
 C>Date: 24-Aug-2001 #sequence_revision 24-Aug-2001 #text_change 30-Sep-2001
 R:Accession: B95846

R:Finan, T.M.; Weidner, S.; Wong, K.; Bunhmerster, J.; Chain, P.; Vorholter, F.J.; Herra
 Proc. Natl. Acad. Sci. U.S.A. 98, 9889-9894, 2001
 A>Title: The complete sequence of the 1,683-kb pSymB megaplasmid from the N2-fixing en
 A:Reference number: A95842; MUID:21396508; PMID:11481431
 A:Accession: B95846
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-82 <KUR>
 A:Cross-references: GB:AL591985; PIDN:CAC48434.1; PID:915139906; GSPDB:GN00167
 A:Experimental source: strain 1021, megaplasmid pSymB
 R:Galibert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, F.; Barloy-Hubler
 eta, D.; Chain, P.; Cowie, A.; Davis, R.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F
 Science 293, 668-672, 2001
 A:Authors: Kahn, D.; Kahn, M.L.; Kaizman, S.; Keating, D.H.; Kisse, E.; Komp, C.; Lelaure
 hebaull, P.; Vandenbol, M.; Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K
 A>Title: The composite genome of the legume symbiont Sinorhizobium meliloti.
 A:Reference number: A96039; MUID:21368234; PMID:11474104
 A:Contents: annotation
 C:Genetics:
 A:Gene: SMD20031
 A:Gene: plasmid

Query Match 22.7%; Score 45; DB 2; Length 82;
 Best Local Similarity 37.5%; Pred. No. 32;
 Matches 9; Conservative 4; Mismatches 11; Indels 0; Gaps 0;

QY 12 SRDPLWKGPATLWKGEGAVIYOD 35
 DB 20 SKDGHWRDPRPLAADQIVITD 43

RESULT 6

AD2538
 hypothetical protein asl7591 [imported] - Nostoc sp. (strain PCC 7120) Plasmid pCC7120b.
 C:Species: Nostoc sp.
 A:Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120
 C>Date: 14-Dec-2001 #sequence_revision 14-Dec-2001 #text_change 30-Jun-2002
 R:Accession: AD2538

R:Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriyuchi
 DNA Res. 8, 205-213, 2001
 A>Title: Complete genomic sequence of the filamentous Nitrogen-fixing Cyanobacterium An
 A:Reference number: AB1807; MUID:21595285; PMID:11759640
 A:Accession: AD2538
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-76 <KUR>
 A:Cross-references: GB:AP003602; PIDN:BAE77234.1; PID:917134676; GSPDB:GN00181
 A:Experimental source: strain PCC 7120
 C:Genetics:
 A:Gene: asl7591
 A:Gene: plasmid

Query Match 21.2%; Score 42; DB 2; Length 76;
 Best Local Similarity 40.0%; Pred. No. 78;
 Matches 6; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

QY 9 YDSDPIMKGPATLWK 23
 DB 3 HQSDSDSWWRSPAKT 17

C:Genetics:
A:Genome: mitochondrion
C:Keywords: mitochondrion

Query Match

Best Local Similarity 31.0%; Score 39.5; DB 2; Length 87;
Pred. No. 2e+02;
Matches *9; Conservative 7; Mismatches 12; Indels 1; Gaps 1;

QY 3 QNPRVYRDSRDLPMKGPATLWKGEGAV 31
DB 31 QNLI-YNORPRHCKGSRMIMTICL 58

RESULT 12

T36458

hypothetical protein SCP43A.35c - Streptomyces coelicolor

C:Species: Streptomyces coelicolor

C>Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 03-Dec-1999

C:Accession: T36458

R:Seeger, K.; Harris, D.; James, K.D.; Parkhill, J.; Barrrell, B.G.; Rajandream, M.A.
submitted to the EMBL Data Library, July 1999

A:Reference number: 221598

A:Accession: T36458

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-88 <SEE>

A:Cross-references: EMBL:AL096837; PIDN:CAB48922.1; GSPDB:GN00070; SCOEDB:SCF43A.35c

A:Experimental source: strain AJ(2)

C:Genetics:

A:Gene: SCOEDB:SCF43A.35c

Query Match

Best Local Similarity 19.9%; Score 39.5; DB 2; Length 88;
Pred. No. 2e+02;
Matches 9; Conservative 3; Mismatches 8; Indels 1; Gaps 1;

QY 10 RDSRDLPMKGPATLWKGEGAV 30
DB 18 RDDRRLKKGD-KVTWSSHGS 37

RESULT 13

T36605

hypothetical protein SCH24.40c - Streptomyces coelicolor (fragment)

C:Species: Streptomyces coelicolor

C>Date: 03-Dec-1999 #sequence_revision 03-Dec-1999 #text_change 03-Dec-1999

C:Accession: T36605

R:Olliver, K.; Harris, D.; James, K.D.; Parkhill, J.; Barrrell, B.G.; Rajandream, M.A.
submitted to the EMBL Data Library, May 1999

A:Reference number: 221575

A:Accession: T36605

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-96 <OLI>

A:Cross-references: EMBL:AL049826; PIDN:CAB42746.1; GSPDB:GN00070; SCOEDB:SCH24.40c

A:Experimental source: strain AJ(2)

C:Genetics:

A:Gene: SCOEDB:SCH24.40c

Query Match

Best Local Similarity 19.9%; Score 39.5; DB 2; Length 96;
Pred. No. 2.3e+02;
Matches 10; Conservative 4; Mismatches 6; Indels 1; Gaps 1;

QY 1 KIONFRVYRDSRDLPMKGPATLWKG 20
DB 25 KVOHFVCHLESMDPSLRHGP 45

RESULT 14

AI2304

hypothetical protein asr3992 [imported] - Nostoc sp. (strain PCC 7120)

C:Species: Nostoc sp.

A:Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120

C>Date: 14-Dec-2001 #sequence_revision 14-Dec-2001 #text_change 30-Jun-2002

C:Accession: AI2304

R:Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriyuch

Nakazaki, N.; Shimo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata,

DNA Res. 8, 205-213, 2001

A>Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium An

A:Reference number: AB1807; MUID:21595285; PMID:11759840

A:Accession: AI2304

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-62 <KUR>

A:Cross-references: GB:BA000019; PIDN:BAH75691.1; PID:G17133127; GSPDB:GN00179

A:Experimental source: strain PCC 7120

C:Genetics:

A:Gene: asr3992

C:Superfamily: conserved hypothetical protein ycf9

Query Match

Best Local Similarity 19.7%; Score 39; DB 2; Length 62;
Pred. No. 1.6e+02;
Matches 7; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 17 WKGPATLWKGEG 29
DB 33 WVESKULWLGSG 45

RESULT 15

T05933

probable 3-methyl-2-oxobutanoate dehydrogenase (lipoamide) (EC 1.2.4.4) alpha chain - b

N:Alternate names: branched-chain alpha-keto acid decarboxylase complex E1-alpha chain

C:Species: Hordeum vulgare (barley)

C>Date: 30-Apr-1999 #sequence_revision 30-Apr-1999 #text_change 20-Jun-2000

C:Accession: T05933

R:Hess, W.R.; Goitz, R.R.; Boerner, T.

Plant Sci. 133, 191-201, 1998

A>Title: Analysis of randomly selected cDNAs reveals the expression of stress- and def

A:Reference number: 215411

A:Accession: T05933

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-64 <HES>

A:Cross-references: EMBL:AJ222787; PIDN:CAH10992.1

A:Experimental source: cv. Haisa, leaf

C:Superfamily: pyruvate dehydrogenase (lipoamide) alpha chain; thiamin pyrophosphate-bi

C:Keywords: mitochondrion; oxidoreductase

Query Match

Best Local Similarity 19.7%; Score 39; DB 2; Length 64;
Pred. No. 1.7e+02;
Matches 6; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 15 PLWKGPAKLWKG 27
DB 11 PYYRREGVILWKG 23

Search completed: May 6, 2003, 14:58:40
Job time: 18 secs

GenCore version 5.1.4 p5 4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 6, 2003, 14:57:29 / Search time 16 Seconds
(without alignments)
194.145 Million cell updates/sec

Title: US-09-868-399-1

Perfect score: 189

Sequence: 1 KIONFRYYRSDRPLWKGPALKMKGGAIVIQDN 36

Scoring table:

BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 328255 seqs, 8628685 residues

Total number of hits satisfying chosen parameters: 125019

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

Published Applications AA:
1: /cgn2_6/ptodata/1/pubppaa/US08_NEW_PUB pep:*
2: /cgn2_6/ptodata/1/pubppaa/PCT_NEW_PUB pep:*
3: /cgn2_6/ptodata/1/pubppaa/US06_NEW_PUB pep:*
4: /cgn2_6/ptodata/1/pubppaa/US06_PUBCOMB pep:*
5: /cgn2_6/ptodata/1/pubppaa/US07_NEW_PUB pep:*
6: /cgn2_6/ptodata/1/pubppaa/US07_PUBCOMB pep:*
7: /cgn2_6/ptodata/1/pubppaa/PCTUS_PUBCOMB pep:*
8: /cgn2_6/ptodata/1/pubppaa/US08_PUBCOMB pep:*
9: /cgn2_6/ptodata/1/pubppaa/US09_NEW_PUB pep:*
10: /cgn2_6/ptodata/1/pubppaa/US09_PUBCOMB pep:*
11: /cgn2_6/ptodata/1/pubppaa/US10_NEW_PUB pep:*
12: /cgn2_6/ptodata/1/pubppaa/US10_PUBCOMB pep:*
13: /cgn2_6/ptodata/1/pubppaa/US60_NEW_PUB pep:*
14: /cgn2_6/ptodata/1/pubppaa/US60_PUBCOMB pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	54	27.3	10	US-09-894-018-161	Sequence 161, App
2	54	27.3	15	US-09-894-018-192	Sequence 192, App
3	49	24.7	9	US-10-106-487-36	Sequence 36, Appl
4	49	24.7	14	US-10-062-710-23	Sequence 23, Appl
5	46.5	23.5	96	US-09-764-868-871	Sequence 871, App
6	46	23.2	38	US-10-082-830-200	Sequence 200, App
7	45.5	23.0	79	US-10-125-540-534	Sequence 534, App
8	45.5	23.0	79	US-09-764-870-534	Sequence 534, App
9	44.5	22.7	93	US-09-764-881-4912	Sequence 4912, App
10	44.5	22.5	93	US-09-764-881-5337	Sequence 5337, App
11	43	21.7	75	US-09-764-877-1243	Sequence 1243, App
12	43	21.7	86	US-09-989-920-243	Sequence 243, App
13	41	20.7	38	US-10-011-585A-230	Sequence 230, App
14	41	20.7	53	US-09-864-761-36417	Sequence 36417, A
15	41	20.7	94	US-09-734-569-120	Sequence 120, App
16	40.5	20.5	77	US-09-864-761-48829	Sequence 48829, A
17	40.5	20.5	86	US-09-796-692-2169	Sequence 2169, App
18	40.5	20.5	86	US-10-040-862-2169	Sequence 2169, App
19	40	20.2	31	US-09-822-540A-2	Sequence 2, Appl

20	40	20.2	31	10	US-09-938-700-2	Sequence 2, Appl
21	40	20.2	34	10	US-09-938-700-6	Sequence 6, Appl
22	40	20.2	38	9	US-10-185-050-34	Sequence 34, Appl
23	40	20.2	39	10	US-09-925-297-756	Sequence 756, App
24	40	20.2	60	10	US-09-864-761-37881	Sequence 37881, A
25	40	20.2	63	10	US-09-822-540A-1	Sequence 1, Appl
26	40	20.2	74	10	US-09-925-300-1663	Sequence 1663, App
27	40	20.2	91	9	US-10-001-857-198	Sequence 198, App
28	40	20.2	93	9	US-10-091-804-760	Sequence 760, App
29	40	20.2	93	10	US-09-764-869-760	Sequence 760, App
30	39.5	19.9	57	10	US-09-879-957-213	Sequence 213, App
31	39.5	19.9	63	9	US-09-925-664-34	Sequence 34, Appl
32	39.5	19.9	70	9	US-10-007-280A-210	Sequence 210, App
33	39	19.7	15	10	US-09-894-018-207	Sequence 207, App
34	39	19.7	49	10	US-09-864-761-37881	Sequence 37881, A
35	39	19.7	51	9	US-10-001-835-202	Sequence 202, App
36	39	19.7	66	9	US-09-796-692-2165	Sequence 2165, App
37	39	19.7	66	9	US-10-040-862-2165	Sequence 2165, App
38	39	19.7	67	10	US-09-864-761-33604	Sequence 33604, A
39	39	19.7	81	10	US-09-864-761-47481	Sequence 47481, A
40	39	19.7	88	10	US-09-864-761-46269	Sequence 46269, A
41	38.5	19.4	38	9	US-10-185-050-18	Sequence 18, Appl
42	38.5	19.4	50	10	US-09-864-761-38860	Sequence 38860, A
43	38	19.2	47	9	US-09-809-391-435	Sequence 435, App
44	38	19.2	56	9	US-09-764-891-3292	Sequence 3292, App
45	38	19.2	56	10	US-09-908-711-116	Sequence 116, App

ALIGNMENTS

RESULT 1
US-09-894-018-161
Sequence 161, Application US/09894018
Patent No. US20020119127A1
GENERAL INFORMATION:
APPLICANT: EPIMUNE, Inc.
APPLICANT: Sette, Alessandro
APPLICANT: Chestnut, Robert
APPLICANT: Livingston, Brian
APPLICANT: Baker, Denlew
APPLICANT: Newman, Mark
APPLICANT: Brown, David
TITLE OF INVENTION: METHODS AND SYSTEM FOR OPTIMIZING
TITLE OF INVENTION: MINIGENES AND PEPTIDES THEREBY
FILE REFERENCE: 39963-20033.00
CURRENT APPLICATION NUMBER: US/09/894,018
CURRENT FILING DATE: 2001-06-27
PRIOR APPLICATION NUMBER: PCT/US00/35568
PRIOR FILING DATE: 2000-12-28
PRIOR APPLICATION NUMBER: US 60/173,390
PRIOR FILING DATE: 1999-12-28
PRIOR APPLICATION NUMBER: US 60/284,221
PRIOR FILING DATE: 2001-04-16
NUMBER OF SEQ ID NOS: 368
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 161
LENGTH: 10
TYPE: PRT
ORGANISM: Transgenic mouse
US-09-894-018-161

Query Match 27.3%, Score 54, DB 10, Length 10;
Best Local Similarity 100.0%, Pred. No. 0.23;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 KIONFRYYR 10
|||
Db 1 KIONFRYYR 10

RESULT 2
US-09-894-018-192

```
Sequence 192, Application US/09894018
Patent No. US20020119127A1
GENERAL INFORMATION:
APPLICANT: EPIMUNE, Inc.
APPLICANT: Sette, Alessandro
APPLICANT: Chesnut, Robert
APPLICANT: Livingston, Brian
APPLICANT: Baker, Denise
APPLICANT: Newman, Mark
APPLICANT: Brown, David
TITLE OF INVENTION: METHODS AND SYSTEM FOR OPTIMIZING
FILE REFERENCE: 39963-2003.00
CURRENT FILING DATE: 2001-06-27
PRIOR APPLICATION NUMBER: PCT/US00/35568
PRIOR FILING DATE: 2000-12-28
PRIOR APPLICATION NUMBER: US 60/173,390
PRIOR FILING DATE: 1999-12-28
PRIOR APPLICATION NUMBER: US 60/284,221
NUMBER OF SEQ ID NOS: 368
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 192
LENGTH: 15
TYPE: PRT
ORGANISM: Transgenic mouse
US-09-894-018-192
```

```
Query Match
Best Local Similarity 27.3%; Score 54; DB 10; Length 15;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 KIONPRVYR 10
Db 6 KIONPRVYR 15
```

```
RESULT 3
US-10-106-487-36
Sequence 36, Application US/10106487
Patent No. US20020164721A1
GENERAL INFORMATION:
APPLICANT: FIRAT, HOSEYIN
APPLICANT: LEMONNIER, FRANCOIS
APPLICANT: LANGLADE-DEMOYEN, PIERRE
APPLICANT: MICHEL, MARIE-LOUISE
TITLE OF INVENTION: DESIGN OF A POLYPEPTIDIC CONSTRUCT FOR THE INDUCTION
TITLE OF INVENTION: OF
TITLE OF INVENTION: H1A-A2.1 RESTRICTED HIV 1 SPECIFIC CTL RESPONSES USING
FILE REFERENCE: 03495.0196 SEQUENCE LISTING
CURRENT FILING DATE: 2002-03-27
PRIOR APPLICATION NUMBER: US/10/106,487
PRIOR FILING DATE: 2000-09-29
PRIOR APPLICATION NUMBER: 60/158,356
NUMBER OF SEQ ID NOS: 41
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 36
LENGTH: 9
TYPE: PRT
ORGANISM: Human immunodeficiency virus type 1
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)
OTHER INFORMATION: L9V MUTANT EPIOTOPE
US-10-106-487-36
```

```
Query Match
Best Local Similarity 24.7%; Score 49; DB 9; Length 9;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 23 LMKGEAV 31
Db 1 LMKGEAV 9
```

```
RESULT 4
US-10-062-710-23
Sequence 23, Application US/10062710
Publication No. US20030049253A1
GENERAL INFORMATION:
APPLICANT: Li, Frank O.
APPLICANT: Chu, Yong-Liang
APPLICANT: Qiu, Jian-Tai
TITLE OF INVENTION: Polymeric Conjugates for Delivery of
TITLE OF INVENTION: MHC-Recognized Epitopes
FILE REFERENCE: 3781-001-27
CURRENT FILING DATE: 2002-02-05
PRIOR APPLICATION NUMBER: US/10/062,710
PRIOR FILING DATE: 2001-08-08
NUMBER OF SEQ ID NOS: 232
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 23
LENGTH: 14
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: HIV Helper-T Cell Epitopes
US-10-062-710-23
```

```
Query Match
Best Local Similarity 24.7%; Score 49; DB 9; Length 14;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY 1 KIONPRVYR 9
Db 6 KIONPRVYR 14
```

```
RESULT 5
US-09-764-868-871
Sequence 871, Application US/09764868
Patent No. US20020168711A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: PT232
CURRENT FILING DATE: 2001-01-17
PRIOR APPLICATION NUMBER: US/09/764,868
PRIOR APPLICATION data removed - refer to PALM or file wrapper
NUMBER OF SEQ ID NOS: 1510
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 871
LENGTH: 96
TYPE: PRT
ORGANISM: Homo sapiens
US-09-764-868-871
```

```
Query Match
Best Local Similarity 23.5%; Score 46.5; DB 9; Length 96;
Matches 13; Conservative 5; Mismatches 11; Indels 9; Gaps 2;
```

```
OY 4 NFRVYRSDRDLKGPAAK-----LW--KGEAV 32
Db 59 NFRVYRSDRDLKGPAAK-----LW--KGEAV 32
```

```
RESULT 6
US-10-082-830-200
Sequence 200, Application US/10082830
Publication No. US20030077604A1
```

```
GENERAL INFORMATION:
APPLICANT: Sun, Yonming
APPLICANT: Recipon, Hervé
APPLICANT: Salceda, Susana
APPLICANT: Liu, Chenghua
APPLICANT: Turner, Leah
TITLE OF INVENTION: Compositions and Methods Relating to Breast Specific
FILE REFERENCE: DEX-0249
CURRENT APPLICATION NUMBER: US/10/082,830
CURRENT FILING DATE: 2001-10-29
PRIORITY FILING DATE: 60/243,802
NUMBER OF SEQ ID NOS: 282
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 200
LENGTH: 38
TYPE: PRT
ORGANISM: Homo sapiens
US-10-082-830-200
```

```
Query Match          23.2%; Score 46; DB 9; Length 38;
Best Local Similarity 43.8%; Pred. No. 12;
Matches 7; Conservative 3; Mismatches 6; Indels 0; Gaps 0;
```

```
QY 2 IONFRVYRDSRDLPLM 17
:|||||:
Db 1 LANFRISRDVSPFCW 16
```

```
RESULT 7
US-10-125-540-534
Sequence 534, Application US/10125540
Publication No. US20030059875A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: PT214C1
CURRENT APPLICATION NUMBER: US/10/125,540
CURRENT FILING DATE: 2002-04-19
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 646
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 534
LENGTH: 79
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: (28)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
FEATURE:
NAME/KEY: misc_feature
LOCATION: (75)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
FEATURE:
NAME/KEY: misc_feature
LOCATION: (76)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-10-125-540-534
```

```
Query Match          23.0%; Score 45.5; DB 9; Length 79;
Best Local Similarity 28.2%; Pred. No. 32;
Matches 11; Conservative 7; Mismatches 10; Indels 11; Gaps 1;
```

```
QY 4 NFRVYRDS-----RDPLMKGPAXLWKGEGAV 31
:|||||:
Db 33 HFSTYYKDNCPHRRKRGHISDGDGSPANSVSKGPGGL 71
```

```
RESULT 8
US-09-764-870-534
Sequence 534, Application US/09764870
```

```
Patent No. US20020042386A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: PT214
CURRENT APPLICATION NUMBER: US/09/764,870
CURRENT FILING DATE: 2001-01-17
Prior application data removed - consult PALM or file wrapper
NUMBER OF SEQ ID NOS: 646
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 534
LENGTH: 79
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: SITE
LOCATION: (28)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
NAME/KEY: SITE
LOCATION: (75)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
NAME/KEY: SITE
LOCATION: (76)
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-870-534
```

```
Query Match          23.0%; Score 45.5; DB 10; Length 79;
Best Local Similarity 28.2%; Pred. No. 32;
Matches 11; Conservative 7; Mismatches 10; Indels 11; Gaps 1;
```

```
QY 4 NFRVYRDS-----RDPLMKGPAXLWKGEGAV 31
:|||||:
Db 33 HFSTYYKDNCPHRRKRGHISDGDGSPANSVSKGPGGL 71
```

```
RESULT 9
US-09-764-891-4912
Sequence 4912, Application US/09764891
Publication No. US20030077808A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: PC006
CURRENT APPLICATION NUMBER: US/09/764,891
CURRENT FILING DATE: 2001-01-17
Prior application data removed - consult PALM or file wrapper
NUMBER OF SEQ ID NOS: 10231
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 4912
LENGTH: 99
TYPE: PRT
ORGANISM: Homo sapiens
US-09-764-891-4912
```

```
Query Match          22.7%; Score 45; DB 9; Length 99;
Best Local Similarity 36.4%; Pred. No. 48;
Matches 8; Conservative 3; Mismatches 11; Indels 0; Gaps 0;
```

```
QY 2 IONFRVYRDSRDLPLMKGPAXL 23
:|||||:
Db 6 IEQFLTIQEGSKDPFWAGRRRL 27
```

```
RESULT 10
US-09-764-891-5337
Sequence 5337, Application US/09764891
Publication No. US20030077808A1
GENERAL INFORMATION:
APPLICANT: Rosen et al.
TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
FILE REFERENCE: PC006
CURRENT APPLICATION NUMBER: US/09/764,891
CURRENT FILING DATE: 2001-01-17
```

; Prior application data removed - consult PALM or file wrapper
 ; NUMBER OF SEQ ID NOS: 10231
 ; SOFTWARE: Patentln Ver. 2.0
 ; SEQ ID NO 5337
 ; LENGTH: 93
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-09-764-891-5337

Query Match 22.5%; Score 44.5; DB 9; Length 93;
 Best Local Similarity 33.3%; Pred. No. 52;
 Matches 10; Conservative 3; Mismatches 12; Indels 5; Gaps 1;

QY 4 NFRVYRDSRDLPMKGPALKMGKGAVALI 33
 DB 60 NCFIFSRDGVSPCMWG-----NSRTPLDLVI 84

RESULT 11
 ; US-09-764-877-1243
 ; Sequence 1243, Application US/09764877
 ; Patent No. US20020147140A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rosen et al.
 ; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
 ; FILE REFERENCE: PC005
 ; CURRENT APPLICATION NUMBER: US/09/764,877
 ; CURRENT FILING DATE: 2001-01-17
 ; Prior application data removed - refer to PALM or file wrapper
 ; NUMBER OF SEQ ID NOS: 4031
 ; SOFTWARE: Patentln Ver. 2.0
 ; SEQ ID NO 1243
 ; LENGTH: 75
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: SITE
 ; LOCATION: (56)
 ; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
 ; NAME/KEY: SITE
 ; LOCATION: (75)
 ; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
 ; US-09-764-877-1243

Query Match 21.7%; Score 43; DB 10; Length 75;
 Best Local Similarity 46.2%; Pred. No. 67;
 Matches *6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 8 YRDSRDLPMKGP 20
 DB 23 YHENTRALMWRGP 35

RESULT 12
 ; US-09-989-920-243
 ; Sequence 243, Application US/09989920
 ; Patent No. US20020172957A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Macina, Roberto
 ; APPLICANT: Recipon, Herve
 ; APPLICANT: Chen, Sei-Yu
 ; APPLICANT: Sun, Yongming
 ; APPLICANT: Liu, Chenghua
 ; TITLE OF INVENTION: Compositions and Methods Relating to Lung Specific Genes and Pro
 ; FILE REFERENCE: DEX-0291
 ; CURRENT APPLICATION NUMBER: US/09/989,920
 ; CURRENT FILING DATE: 2001-11-21
 ; PRIOR APPLICATION NUMBER: 60/252,500
 ; PRIOR FILING DATE: 2000-11-22
 ; NUMBER OF SEQ ID NOS: 284
 ; SOFTWARE: Patentln version 3.1
 ; SEQ ID NO 243
 ; LENGTH: 86

; TYPE: PRT
 ; ORGANISM: Homo sapien
 ; US-09-989-920-243

Query Match 21.7%; Score 43; DB 9; Length 86;
 Best Local Similarity 50.0%; Pred. No. 77;
 Matches 8; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

QY 4 NFRVYRDSRDLPMKGP 19
 DB 49 NCFVGRDGVSPCMWG 64

RESULT 13
 ; US-10-011-585A-230
 ; Sequence 230, Application US/10011585A
 ; Publication No. US2003003986A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sun, Yongming
 ; APPLICANT: Recipon, Herve
 ; APPLICANT: Chen, Sei-Yu
 ; APPLICANT: Liu, Chenghua
 ; TITLE OF INVENTION: Genes and Proteins
 ; FILE REFERENCE: DEX-0261
 ; CURRENT APPLICATION NUMBER: US/10/011,585A
 ; CURRENT FILING DATE: 2002-03-14
 ; PRIOR APPLICATION NUMBER: 60/245,740
 ; PRIOR FILING DATE: 2000-11-03
 ; NUMBER OF SEQ ID NOS: 245
 ; SOFTWARE: Patentln Ver. 2.1
 ; SEQ ID NO 230
 ; LENGTH: 38
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: UNSURE
 ; LOCATION: (27)
 ; OTHER INFORMATION: any amino acid
 ; US-10-011-585A-230

Query Match 20.7%; Score 41; DB 9; Length 38;
 Best Local Similarity 41.9%; Pred. No. 60;
 Matches 13; Conservative 6; Mismatches 6; Indels 6; Gaps 2;

QY 10 RDSRDLPMKGPALKL---WKEGAVIODN 36
 DB 9 RDSRDLPMKGPALKL---WKEGAVIODN 37

RESULT 14
 ; US-09-864-761-36417
 ; Sequence 36417, Application US/09864761
 ; Patent No. US20020048763A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Penn, Sharon G.
 ; APPLICANT: Rank, David R.
 ; APPLICANT: Hanzel, David K.
 ; APPLICANT: Chen, Wensheng
 ; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
 ; FILE REFERENCE: Aecmca-X-1
 ; CURRENT APPLICATION NUMBER: US/09/864,761
 ; CURRENT FILING DATE: 2001-05-23
 ; PRIOR APPLICATION NUMBER: US 60/180,312
 ; PRIOR FILING DATE: 2000-02-04
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: US 09/632,366
 ; PRIOR FILING DATE: 2000-08-03
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359


```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Annonax Sequence Listing Engine vers. 1.1
; SEQ ID NO 36417
; LENGTH: 53
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC007322.2
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 8.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 7.6
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 5.6
; OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 5.7
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 4
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 4.2
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 7
; OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 6.5
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 8.7
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 7.6
; OTHER INFORMATION: EST_HUMAN HIT: AA196978.1, EVALU 3.30e-01
US-09-864-761-36417

Query Match 20.7%; Score 41; DB 10; Length 53;
Best Local Similarity 58.3%; Pred. No. 86;
Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 25 WKGGCAVVIQDN 36
Db 1 WKGSAAVLIADH 12

RESULT 15
US-09-734-569-120
; Sequence 120, Application US/09734569
; Patent No. US20020064816A1
; GENERAL INFORMATION:
; APPLICANT: Lersch, Jens
; APPLICANT: Renz, Andreas
; APPLICANT: Enhardt, Thomas
; APPLICANT: Reindl, Andreas
; APPLICANT: Clippus, Petra
; APPLICANT: Bischoff, Friedrich
; APPLICANT: Frank, Markus
; APPLICANT: Freund, Annette
; APPLICANT: Duwenig, Elke
; APPLICANT: Schmidt, Ralf-Michael
; APPLICANT: Reekl, Ralf
```

```

; TITLE OF INVENTION: Moss genes from Physcomitrella patens encoding proteins involved
; TITLE OF INVENTION: in the synthesis of carbohydrates
; FILE REFERENCE: BASF-NAE-1332-99-US
; CURRENT APPLICATION NUMBER: US/09/734,569
; PRIOR FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: 1999-12-16
; NUMBER OF SEQ ID NOS: 181
; SOFTWARE: PatentIn Ver. 2.1/WordPerfect 6.1
; SEQ ID NO 120
; LENGTH: 94
; TYPE: PRT
; ORGANISM: Physcomitrella patens
US-09-734-569-120

Query Match 20.7%; Score 41; DB 10; Length 94;
Best Local Similarity 40.6%; Pred. No. 1.6e+02;
Matches 13; Conservative 4; Mismatches 11; Indels 4; Gaps 1;

QY 7 VYRDSRDP---LWKGPALKWKGGCAVVIQ 34
Db 35 VKYGSMDAFKQIIAKGSAKSLFKGAGNIIR 66

Search completed: May 6, 2003, 14:59:23
Job time : 17 secs
```


GenCore version 5.1.4 p5 4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 6, 2003, 14:56:49 ; Search time 15 Seconds
(without alignments)
70.615 Million cell updates/sec

Title: US-09-868-399-1
Perfect score: 198
Sequence: 1 KIGNFRYYRDSRDLPMKGPALKLMKGGAIVIQDN 36

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 196705

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA.*
1: /cgn2_6/ptodata/1/1aa/5A.COMB.pep.*
2: /cgn2_6/ptodata/1/1aa/5B.COMB.pep.*
3: /cgn2_6/ptodata/1/1aa/6A.COMB.pep.*
4: /cgn2_6/ptodata/1/1aa/6B.COMB.pep.*
5: /cgn2_6/ptodata/1/1aa/PTUS.COMB.pep.*
6: /cgn2_6/ptodata/1/1aa/backfile1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	79	39.9	15	4	US-09-009-953-221
2	58	29.3	43	2	US-08-468-161-67
3	58	29.3	43	3	US-09-273-685-67
4	58	29.3	43	5	PCT-US95-11934-67
5	54	27.3	10	3	US-08-159-339A-550
6	54	27.3	15	4	US-09-009-953-220
7	53	26.8	9	2	US-08-986-234-71
8	53	26.8	10	4	US-08-197-484-74
9	53	26.8	10	5	PCT-US95-02121-74
10	49	24.7	9	2	US-08-986-234-72
11	49	24.7	9	4	US-08-197-484-75
12	49	24.7	9	5	PCT-US95-02121-75
13	49	24.7	11	3	US-08-159-339A-1140
14	48	24.2	15	4	US-09-255-502-6
15	46	23.2	43	2	US-08-468-161-51
16	46	23.2	43	3	US-09-273-685-51
17	46	23.2	43	5	PCT-US95-11934-51
18	44	22.2	30	4	US-09-315-304B-1521
19	44	22.2	67	3	US-08-475-668A-210
20	44	22.2	67	3	US-08-475-668A-210
21	44	22.2	77	3	US-08-475-668A-211
22	44	22.2	77	3	US-08-485-551A-211
23	43	21.7	34	1	US-08-257-528B-26
24	43	21.7	34	1	US-08-460-602A-26
25	43	21.7	34	1	US-08-463-966A-26
26	43	21.7	34	1	US-08-465-217A-26
27	43	21.7	34	2	US-08-464-329A-26

28	43	21.7	34	2	US-08-462-507A-26	Sequence 26, App1
29	43	21.7	34	2	US-08-467-881A-26	Sequence 26, App1
30	43	21.7	34	4	US-08-750-624-4	Sequence 4, App1
31	43	21.7	37	1	US-08-257-528B-39	Sequence 39, App1
32	43	21.7	37	1	US-08-460-602A-39	Sequence 39, App1
33	43	21.7	37	1	US-08-463-966A-39	Sequence 39, App1
34	43	21.7	37	1	US-08-465-217A-39	Sequence 39, App1
35	43	21.7	37	2	US-08-464-529A-39	Sequence 39, App1
36	43	21.7	37	2	US-08-462-507A-39	Sequence 39, App1
37	43	21.7	37	2	US-08-467-881A-39	Sequence 39, App1
38	43	21.7	40	1	US-08-426-819A-19	Sequence 19, App1
39	41.5	21.0	66	4	US-09-082-593-6	Sequence 6, App1
40	41	20.7	44	1	US-08-257-528B-95	Sequence 95, App1
41	41	20.7	44	1	US-08-460-602A-95	Sequence 95, App1
42	41	20.7	44	1	US-08-463-966A-95	Sequence 95, App1
43	41	20.7	44	1	US-08-465-217A-95	Sequence 95, App1
44	41	20.7	44	2	US-08-464-329A-95	Sequence 95, App1
45	41	20.7	44	2	US-08-462-507A-95	Sequence 95, App1

ALIGNMENTS

RESULT 1
US-09-009-953-221
Sequence 221, Application US/09009953
Patent No. 6413517
GENERAL INFORMATION:
APPLICANT: Setite, Alessandro
TITLE OF INVENTION: Identification of Broadly Reactive DR Restricted Epitopes
NUMBER OF SEQUENCES: 274
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,953
FILING DATE: 21-Jan-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/036,713
FILING DATE: 23-JAN-1997
APPLICATION NUMBER: US 60/037,432
FILING DATE: 07-FEB-1997
ATTORNEY/AGENT INFORMATION:
NAME: Weber, Ellen Lauver
REGISTRATION NUMBER: 32,762
REFERENCE/DOCKET NUMBER: 018623-011520US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-576-0200
TELEFAX: 415-576-0300
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 221:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 221:
US-09-009-953-221
Query Match 39.9%; Score 79; DB 4; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e-05;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 22 KLMKGAGVAVTQDN 36

Db 1 KLMKGAGVAVTQDN 15

RESULT 2

US-08-488-161-67

Sequence 67, Application US/08488161
Patent No. 5885577

GENERAL INFORMATION:

APPLICANT: Alvarez, Vernon L.

TITLE OF INVENTION: Antigen Binding Peptides (Abptides) From

NUMBER OF SEQUENCES: 103

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie & Edmonds

STREET: 1155 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/488,161

FILING DATE: 07-JUN-1995

CLASSIFICATION: 436

ATTORNEY/AGENT INFORMATION:

NAME: Mistrock, S. Leslie

REGISTRATION NUMBER: 18,872

REFERENCE/DOCKET NUMBER: 1101-176

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 790-9090

TELEFAX: (212) 869-9741/8864

TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 67:

SEQUENCE CHARACTERISTICS:

LENGTH: 43 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-08-488-161-67

Query Match

Best Local Similarity 66.7%; Score 58; DB 2; Length 43;

Matches 10; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 15 PLWKGPAKLMKGEG 29

Db 9 PPMGSPAGLWGGCG 23

RESULT 3

US-09-273-685-67

Sequence 67, Application US/09273685

Patent No. 6015561

GENERAL INFORMATION:

APPLICANT: Alvarez, Vernon L.

TITLE OF INVENTION: Antigen Binding Peptides (Abptides) From

NUMBER OF SEQUENCES: 103

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie & Edmonds

STREET: 1155 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/11934

FILING DATE: 20-SEP-1995

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Mistrock, S. Leslie

REGISTRATION NUMBER: 18,872

REFERENCE/DOCKET NUMBER: 1101-196-228

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 790-9090

TELEFAX: (212) 869-9741/8864

TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 67:

SEQUENCE CHARACTERISTICS:

LENGTH: 43 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-09-273-685-67

Query Match

Best Local Similarity 66.7%; Score 58; DB 3; Length 43;

Matches 10; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 15 PLWKGPAKLMKGEG 29

Db 9 PPMGSPAGLWGGCG 23

RESULT 4

PCT-US95-11934-67

Sequence 67, Application PC/TUS9511934

GENERAL INFORMATION:

APPLICANT: Cyrogen Corporation

TITLE OF INVENTION: Antigen Binding Peptides (Abptides) From

NUMBER OF SEQUENCES: 103

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pennie & Edmonds

STREET: 1155 Avenue of the Americas

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US95/11934

FILING DATE: 20-SEP-1995

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Mistrock, S. Leslie

REGISTRATION NUMBER: 18,872

REFERENCE/DOCKET NUMBER: 1101-196-228

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 790-9090

TELEFAX: (212) 869-9741/8864

TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 67:

SEQUENCE CHARACTERISTICS:

LENGTH: 43 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

US-09-273-685-67

Query Match

Best Local Similarity 66.7%; Score 58; DB 3; Length 43;

Matches 10; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 15 PLWKGPAKLMKGEG 29

Db 9 PPMGSPAGLWGGCG 23

```

; LENGTH: 43 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
PCT-US95-11934-67

```

Query Match	29.3%;	Score 58;	DB 5;	Length 43;
Best Local Similarity	66.7%;	Pred. No. 0.083;		
Matches 10;	Conservative	1;	Mismatches	4;
			Indels	

QY	15	PLWKGPAKLWKGE	29
		:	
Db	9	PPWSGPAGLWQCG	23

RESULT 5
US-08-159-339A-550
; Sequence 550, Application US/08159339A

1 GENERAL INFORMATION:
2 APPLICANT: Kubo, Ralph T.
3 APPLICANT: Grey, Howard M.
4 APPLICANT: Sette, Alessandro
5 APPLICANT: Celis, Esteban
6 TITLE OF INVENTION: HLA Binding peptides and Their
7 TITLE OF INVENTION: Uses
8 NUMBER OF SEQUENCES: 1254
9 CORRESPONDENCE ADDRESS:

```

1  COUNTRY: USA
2  ZIP: 94111-3834
3  COMPUTER READABLE FORM:
4  MEDIA TYPE: Diskette
5  COMPUTER: IBM Compatible
6  OPERATING SYSTEM: DOS
7  SOFTWARE: FASTSEO for Windows Version 2.0
8  CURRENT APPLICATION DATA:

```

```

; INFORMATION FOR SEQ ID NO: 550:
;
; SEQUENCE CHARACTERISTICS:
;
; LENGTH: 10 amino acids
;
; TYPE: amino acid
;
; STRANDEDNESS: single
;
; TOPOLOGY: linear
;
; MOLECULE TYPE: peptide
;
; OS=08-159-339A-550

```

Query Match	27.3%;	Score 54;	DB 3;	Length 10;
Best Local Similarity	100.0%;	Pred. No. 0.058;		
Matches	10;	Conservative	0;	Mismatches 0;
				Indels

QY 1 KIONFRVYR 10

Db 1 KIQNFRVYYR 10

RESULT 6
US-09-009-953-220
; Sequence 220, Application US/09009953

1 GENERAL INFORMATION:
2 APPLICANT: Sette, Alessandro
3 TITLE OF INVENTION: Identification of Broadly
4 Reactive DR Restricted Epitopes
5
6 NUMBER OF SEQUENCES: 274
7
8 CORRESPONDENCE ADDRESS:
9 ADDRESSEE: Townsend and Crew LLP
10 STEERY: Two Embarcadero Center, Eighth Floor
11 CITY: San Francisco

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,953
FILING DATE: 21-Jan-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/036,713
FILING DATE: 23-Jan-1997
APPLICATION NUMBER: US 60/037,432
FILING DATE: 07-FEB-1997

```

? INFORMATION FOR SEQ ID NO: 220:
?     SEQUENCE CHARACTERISTICS:
?         LENGTH: 15 amino acids
?         TYPE: amino acid
?         STRANDEDNESS: single
?         TOPOLOGY: linear
?     MOLECULE TYPE: peptide
?     SEQUENCE DESCRIPTION: SEQ ID NO: 220
US-09-009-953-220

```

Query Match	27.3%	Score 54	DB 4	Length 15
Best Local Similarity	100.0%	Pred. No. 0.094		
Match 10	Conservative	0	Mismatches	0
			Indels	0
			Gaps	0

QY	1	KIQNFRVYYR	10
Db	6	KIQNFRVYYR	15

```

RESULT 7
US-08-986-234-71
: Sequence 71. Application US/08986234
: Patent No. 5981706
: GENERAL INFORMATION:
: APPLICANT: Wallen, et al.
: TITLE OF INVENTION: Methods for Synthesizing Heat Shock Protein Complexes
: FILE REFERENCE: UMW-0008-1
: CURRENT APPLICATION NUMBER: US/08/986,234
: CURRENT FILING DATE: 1997-12-05
: NUMBER OF SEQ ID NOS: 114
: SOFTWARE: PatentIn Ver. 2.0

```

SEQ ID NO 71
LENGTH: 9
TYPE: PRT
ORGANISM: Human immunodeficiency virus
US-08-986-234-71

Query Match 26.8%; Score 53; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 LLMKGPAKL 23
DB 1 LLMKGPAKL 9

RESULT 8
US-08-197-484-74
Sequence 74, Application US/08197484
Patent No. 6419931
GENERAL INFORMATION:
APPLICANT: VITTELO, Maria A.
APPLICANT: CHESTNUT, Robert W.
APPLICANT: SETTE, Alessandro D.
APPLICANT: CELIS, Esteban
APPLICANT: GRAY, Howard
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: Steuart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/197,484
FILING DATE: 16-FEB-1994
CLASSIFICATION: 424
APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 467-9600
TELEFAX: (206) 467-9600
INFORMATION FOR SEQ ID NO: 74:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
US-08-197-484-74

Query Match 26.8%; Score 53; DB 4; Length 10;

Best Local Similarity 100.0%; Pred. No. 0.082;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 LLMKGAVV 32
DB 1 LLMKGAVV 10

RESULT 9
PCT-US95-02121-74
Sequence 74, Application PC/TUS9502121
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/02121
FILING DATE: 16-FEB-1995
CLASSIFICATION:
APPLICATION NUMBER: US 08/197,484
FILING DATE: 16-FEB-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4PC
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 543-5043
TELEFAX: (206) 467-9600
INFORMATION FOR SEQ ID NO: 74:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
PCT-US95-02121-74

Query Match 26.8%; Score 53; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.082;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 LLMKGAVV 32
DB 1 LLMKGAVV 10

RESULT 10
US-08-986-234-72
Sequence 72, Application US/08986234
Patent No. 5981706
GENERAL INFORMATION:
APPLICANT: Wallen, et al.
TITLE OF INVENTION: Methods for Synthesizing Heat Shock Protein Complexes
FILE REFERENCE: UNME-0008-1

MOLECULE TYPE: peptide
US-08-197-484-75
CURRENT APPLICATION NUMBER: US/08/986,234
CURRENT FILING DATE: 1997-12-05
NUMBER OF SEQ ID NOS: 114
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 72
LENGTH: 9
TYPE: PRT
ORGANISM: Human immunodeficiency virus
US-08-986-234-72

Query Match
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 LMKGEAV 31
Db 1 LMKGEAV 9

RESULT 11
US-08-197-484-75
Sequence 75, Application US/08197484
Patent No. 6419931
GENERAL INFORMATION:
APPLICANT: VITTELLO, Maria A.
APPLICANT: CHESTNUT, Robert W.
APPLICANT: SETTE, Alessandro D.
APPLICANT: CELIS, Estebean
APPLICANT: GRAY, Howard
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: Steuart Street Tower, One Market Plaza
CITY: San Francisco
STATE: California
COUNTRY: US
ZIP: 94105-1493
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/197,484
FILING DATE: 16-FEB-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 467-9600
TELEFAX: (206) 623-6793
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown

MOLECULE TYPE: peptide
US-08-197-484-75
CURRENT APPLICATION NUMBER: US/08/986,234
CURRENT FILING DATE: 1997-12-05
NUMBER OF SEQ ID NOS: 114
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 72
LENGTH: 9
TYPE: PRT
ORGANISM: Human immunodeficiency virus
US-08-986-234-72

Query Match
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 LMKGEAV 31
Db 1 LMKGEAV 9

RESULT 12
PCT-US95-02121-75
Sequence 75, Application PC/TUS9502121
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ELICITING
TITLE OF INVENTION: CTL IMMUNITY
NUMBER OF SEQUENCES: 153
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/02121
FILING DATE: 16-FEB-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/197,484
FILING DATE: 16-FEB-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/935,811
FILING DATE: 26-AUG-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/874,491
FILING DATE: 27-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,682
FILING DATE: 29-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/749,568
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14137-26-4PC
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 467-9600
TELEFAX: (415) 543-5043
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: peptide
PCT-US95-02121-75

Query Match
Best Local Similarity 100.0%; Pred. No. 1.9e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 LMKGEAV 31
Db 1 LMKGEAV 9

RESULT 13
US-08-159-339A-1140
Sequence 1140, Application US/08159339A
Patent No. 6037135

GENERAL INFORMATION:
APPLICANT: Kubo, Ralph T.
APPLICANT: Grey, Howard M.
APPLICANT: Sette, Alessandro
APPLICANT: Celis, Esteban
TITLE OF INVENTION: HLA Binding peptides and Their
TITLE OF INVENTION: Uses
NUMBER OF SEQUENCES: 1254
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
City: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/159,339A
FILING DATE: 29-NOV-1993
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/926,666
FILING DATE: 07-AUG-1992
APPLICATION NUMBER: US 08/027,746
FILING DATE: 05-MAR-1993
APPLICATION NUMBER: US 08/103,396
FILING DATE: 06-AUG-1993
ATTORNEY/AGENT INFORMATION:
NAME: Weber, Ellen Lauver
REGISTRATION NUMBER: 32,762
REFERENCE/DOCKET NUMBER: 018623-005030US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
TELEX:
INFORMATION FOR SEQ ID NO: 1140:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-159-339A-1140
Query Match 24.7%; Score 49; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 KIONFRVY 9.
Db 3 KIONFRVY 11
RESULT 14
US-09-255-502-6
Sequence 6, Application US/09255502
Patent No. 6218165
GENERAL INFORMATION:
APPLICANT: Estell, David
APPLICANT: Harding, Fiona
TITLE OF INVENTION: Mutant Proteins Having Lower Allergenic Responses in
TITLE OF INVENTION: Humans and Methods for Constructing, Identifying and
FILE REFERENCE: GC 527-D2
CURRENT APPLICATION NUMBER: US/09/255,502
PRIOR APPLICATION NUMBER: 09/060,872
PRIOR FILING DATE: 1998-04-15
NUMBER OF SEQ ID NOS: 7

SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 6
LENGTH: 15
TYPE: PRT
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Description of Unknown Organism: Unknown Sequence
US-09-255-502-6

Query Match 24.2%; Score 48; DB 4; Length 15;
Best Local Similarity 61.5%; Pred. No. 0.72;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2 IONFRVYRDSRD 14
Db 1 IONFRVYRDSRD 13

RESULT 15
US-08-488-161-51
Sequence 51, Application US/08488161
Patent No. 5885577
GENERAL INFORMATION:
APPLICANT: Alvarez, Vernon L.
TITLE OF INVENTION: Antigen Binding Peptides (Abtides) From
NUMBER OF SEQUENCES: 103
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
City: New York
STATE: New York
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,161
FILING DATE: 07-JUN-1995
CLASSIFICATION: 436
ATTORNEY/AGENT INFORMATION:
NAME: Mirock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 1101-176
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 869-9741/8864
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 43 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-08-488-161-51
Query Match 23.2%; Score 46; DB 2; Length 43;
Best Local Similarity 43.8%; Pred. No. 4.9;
Matches 7; Conservative 2; Mismatches 7; Indels 0; Gaps 0;
QY 14 DPLMKGPXKLMKGG 29
Db 8 NPMRGPGGFKMPCG 23
Search completed: May 6, 2003, 14:59:00
Job time : 16 secs

GenCore version 5.1.4.p5 4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 6, 2003, 14:54:59 ; Search time 34 Seconds
(without alignments)
141.089 Million cell updates/sec

Title: US-09-868-399-1
Perfect score: 198
Sequence: 1 KIQNFVRYRDSRDLPMKGPALKLMKGEAVIQDN 36

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 575469

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

A.GeneSeq_101002:*

- 1: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1980.DAT:*
- 2: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1981.DAT:*
- 3: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1982.DAT:*
- 4: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1983.DAT:*
- 5: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1984.DAT:*
- 6: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1985.DAT:*
- 7: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1986.DAT:*
- 8: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1987.DAT:*
- 9: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1988.DAT:*
- 10: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1989.DAT:*
- 11: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1990.DAT:*
- 12: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1991.DAT:*
- 13: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1992.DAT:*
- 14: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1993.DAT:*
- 15: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1994.DAT:*
- 16: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1995.DAT:*
- 17: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1996.DAT:*
- 18: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1997.DAT:*
- 19: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1998.DAT:*
- 20: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA1999.DAT:*
- 21: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA2000.DAT:*
- 22: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA2001.DAT:*
- 23: /SIDS2/gcgdata/geneSeq/geneSeq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	198	100.0	36	21	AA15399
2	169	85.4	31	9	AA182730
3	169	85.4	50	9	AA182728
4	161	81.3	30	23	AA184494
5	110	55.6	30	23	AA184493
6	90	45.5	15	22	ABP24758
7	88	44.4	15	22	ABP24701
8	88	44.4	15	22	ABP25020
9	86	43.4	15	22	ABP24677
10	86	43.4	15	22	ABP25016

11	83	41.9	30	23	AA184495	HIV POL segment 64
12	79	39.9	15	29	AA185346	Helper T-cell clas
13	79	39.9	15	22	ABP24643	HIV DR super motif
14	70	35.4	15	11	AA1803899	HIV antibody react
15	69	34.8	15	22	ABP24663	HIV DR super motif
16	68	34.3	11	22	ABP19154	HIV B62 super motif
17	66	33.3	11	22	ABP19309	HIV B62 super motif
18	62	31.3	10	22	ABP16223	HIV A24 super motif
19	62	31.3	10	22	ABP24215	HIV A24 motif pol
20	61	30.8	10	22	ABP16227	HIV A24 super motif
21	61	30.8	10	22	ABP21162	HIV A03 motif pol
22	61	30.8	10	22	ABP24230	HIV A24 motif pol
23	61	30.8	11	22	ABP13975	HIV A02 super motif
24	61	30.8	11	22	ABP16925	HIV B07 super motif
25	60	30.3	10	22	ABP16222	HIV A03 super motif
26	60	30.3	10	22	ABP21190	HIV A03 motif pol
27	60	30.3	10	22	ABP23194	HIV A11 motif pol
28	60	30.3	10	22	ABP24264	HIV A02 super motif
29	59	29.8	11	22	ABP13974	HIV A02 super motif
30	59	29.8	10	22	ABP16226	HIV A24 super motif
31	59	29.8	10	22	ABP16893	HIV B07 super motif
32	59	29.8	10	22	ABP16926	HIV B07 super motif
33	59	29.8	10	22	ABP21518	HIV A03 super motif
34	59	29.8	10	22	ABP24268	HIV A03 motif pol
35	58	29.3	10	22	ABP21515	HIV A03 motif pol
36	58	29.3	10	22	ABP23424	HIV A11 motif pol
37	58	29.3	11	22	ABP13973	HIV A02 super motif
38	58	29.3	11	22	ABP13976	HIV A02 super motif
39	58	29.3	11	22	ABP16382	HIV A24 super motif
40	58	29.3	11	22	ABP19302	HIV B62 super motif
41	58	29.3	11	22	ABP19464	E88, monoclonal an
42	58	29.3	43	17	AA195500	HIV B27 super motif
43	57	28.8	9	22	ABP17386	HIV A01 super motif
44	57	28.8	10	22	ABP11884	HIV A02 super motif
45	57	28.8	10	22	ABP13740	HIV A02 super motif

ALIGNMENTS

RESULT 1
AA15399
ID AA15399 standard; peptide; 36 AA.
AC AA15399;
DT 15-DEC-2000 (first entry)
XX
DE HIV integrase peptide epitope.
KW Detection; infection; HIV-1; antigen; pol; mixotrope; epitope; integrase;
KW combinatorial peptide; antibody.
XX
OS Human immunodeficiency virus type 1.
XX
PN WO200040970-A1.
XX
PD 13-JUL-2000.
XX
PF 29-DEC-1999; 99WO-FR0311.
XX
PR 31-DEC-1998; 98FR-0016727.
XX
PA (INSP) INST PASTEUR LILLE.
PA (CNRS) CNRS CENT NAT RECH SCI.
XX (GRAS/) GRAS-MASSSE H.
XX
PI Tranchand-Bunel D, Auriant C;
XX
DR WPI; 2000-475858/41.
XX
PT Reagent for detecting human immune deficiency virus infection, useful
for diagnosis and monitoring, comprises pol-derived antigen and mixture

PT of its convergent peptides -
XX
PS Claim 3; Page 15; 32pp; French.
XX
CC The invention relates to a reagent for detecting infection by human
CC immunodeficiency virus (HIV), comprising a mixture of an antigenic
CC peptide encoded by the pol gene and containing at most 60 (preferably
CC 20-40) amino acids, and a mixture, designated a mixotope, of converged,
CC combinatorial peptides derived from the antigenic peptide. This sequence
CC corresponds to an epitope from the integrase protein encoded by the pol
CC gene from HIV-1. The reagent is used to detect anti-HIV antibodies,
CC specifically for diagnosis and monitoring of infection.
XX
SQ Sequence 36 AA;

Query Match 100.0%; Score 198; DB 21; Length 36;
Best Local Similarity 100.0%; Pred. No. 2.8e-22;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIQNFRVYRDSRDP LMKGPATLWKGGAVYIQDN 36
Db 1 KIQNFRVYRDSRDP LMKGPATLWKGGAVYIQDN 36

RESULT 2
AAP82730
ID AAP82730 standard; protein; 31 AA.
XX
AC AAP82730;
XX
DT 23-NOV-1990 (first entry)
XX
DE Immunologically mimicking peptide.
XX
KW Immunological mimicry; HIV gag and pol; AIDS.
XX
OS synthetic.
XX
PN EP267802-A.
XX
PD 18-MAY-1988.
XX
PF 13-NOV-1987; 87EP-0310047.
XX
PR 14-NOV-1986; 86US-0930785.
XX
PA (GENE-) GENETIC SYST CORP.
XX
PI Cosand WL, Harris LJ, Houghton RL;
XX
DR WPI; 1988-134645/20.
DR N-PSDB; AAN82239.
XX
PT Synthetic peptide(s) having sequence corresp. to HIV virus - used
PT for detection of AIDS-related disease and in vaccine prepn.
XX
PS Claim 14; Page 12; 12pp; English.
XX
CC This peptide immunologically mimics a protein encoded by the HIV
CC retrovirus and corresponds to part of peptide 123. It is competitive
CC with HIV and complexes formed on binding of antibodies are detected.
CC It is therefore used as an accurate test for detecting patients who
CC have been exposed to the aetiological agent of lymphadenopathy
CC syndrome and/or AIDS. Residue 31 can be absent but is opt. present.
CC See also AAN82236-38.
XX
SQ Sequence 31 AA;

Query Match 85.4%; Score 169; DB 9; Length 31;
Best Local Similarity 100.0%; Pred. No. 5e-18;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIQNFRVYRDSRDP LMKGPATLWKGGEGA 30

Db 1 KIQNFRVYRDSRDP LMKGPATLWKGGEGA 30

RESULT 3
AAP82728
ID AAP82728 standard; protein; 50 AA.
XX
AC AAP82728;
XX
DT 23-NOV-1990 (first entry)
XX
DE Immunologically mimicking peptide.
XX
KW Immunological mimicry; HIV gag and pol; AIDS.
XX
OS synthetic.
XX
PN EP267802-A.
XX
PD 18-MAY-1988.
XX
PF 13-NOV-1987; 87EP-0310047.
XX
PR 14-NOV-1986; 86US-0930785.
XX
PA (GENE-) GENETIC SYST CORP.
XX
PI Cosand WL, Harris LJ, Houghton RL;
XX
DR WPI; 1988-134645/20.
DR N-PSDB; AAN82237.
XX
PT Synthetic peptide(s) having sequence corresp. to HIV virus - used
PT for detection of AIDS-related disease and in vaccine prepn.
XX
PS Claim 14; Page 12; 12pp; English.
XX
CC This peptide which immunologically mimics a protein encoded by the
CC HIV retrovirus corresponds to amino acids 4385 to 4519 of pol
CC protein p31. It is competitive with HIV and complexes formed on
CC binding of antibodies are detected. It is therefore used as an
CC accurate test for detecting patients who have been exposed to the
CC aetiological agent of lymphadenopathy syndrome and/or AIDS.
CC Residues 1-4 and 50 can be absent but are opt. present.
CC See also AAN82236 and AAN82238-39.
XX
SQ Sequence 50 AA;

Query Match 85.4%; Score 169; DB 9; Length 50;
Best Local Similarity 100.0%; Pred. No. 8.9e-18;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 KIQNFRVYRDSRDP LMKGPATLWKGGEGA 30
Db 20 KIQNFRVYRDSRDP LMKGPATLWKGGEGA 49

RESULT 4
AAU84494
ID AAU84494 standard; peptide; 30 AA.
XX
AC AAU84494;
XX
DT 08-MAY-2002 (first entry)
XX
DE HIV POL segment 63.
XX
KW Savine; vaccine; cancer; viral infection; HIV; hepatitis C virus;
KW viral infection; human immunodeficiency virus; melanoma;
KW bacterial infection; Salmonella; Legionella; parasitic infection;
KW Trypanosoma; Toxoplasma; Giardia.
XX

OS Human immunodeficiency virus type 1.
 OS Synthetic.
 PN WO200190197-A1.
 PD 29-NOV-2001.
 XX 25-MAY-2001; 2001WO-AU00622.
 XX 26-MAY-2000; 2000AU-0007761.
 PR (AUSU) UNIV AUSTRALIAN NAT.
 PA
 PI Thomson SA, Ramshaw IA;
 DR WPI; 2002-147575/19.
 DR N-PSDB; ABK36333.
 XX
 PT New synthetic polypeptides having several different segments of at
 PT least one parent polypeptide linked together differently compared to
 PT the linkage in the parent polypeptide, for inducing immune response
 PT against a pathogen or cancer
 XX
 PS Example 1; Fig 12; 364pp; English.
 CC The invention relates to a new synthetic polypeptide (I) comprising
 CC several different segments of at least one parent polypeptide linked
 CC together in a different relationship relative to their linkage in the
 CC parent polypeptide to impede, abrogate or otherwise alter at least one
 CC function associated with the parent polypeptide and for inducing an
 CC immune response against a pathogen or cancer. Also included are a
 CC synthetic polynucleotide encoding and a computer system for
 CC designing the synthetic polypeptides. The synthetic polypeptides and
 CC polynucleotides are referred to as a Savine. The synthetic polypeptide is
 CC useful for modulating immune responses preferably directed against a
 CC pathogen or a cancer, (e.g., cancers of the lung, breast, ovary, cervix,
 CC colon, head and neck, pancreas, prostate, stomach, bladder, kidney, bone
 CC liver, oesophagus, brain, testicle, uterus), as potentiating agents.
 CC Compositions comprising the polypeptide may be used in the treatment or
 CC prophylaxis against viral (such as infections caused by HIV (human
 CC immunodeficiency virus), hepatitis, influenza, Japanese encephalitis
 CC virus, Epstein-Barr virus and respiratory syncytial virus), bacterial
 CC (e.g., infections caused by Neisseria, Meningococcal, Haemophilus,
 CC Salmonella, Streptococcal, Legionella and Mycobacterium or parasitic
 CC (e.g., infections caused by Plasmodium, Schistosoma, Leishmania,
 CC Trypanosoma, Toxoplasma and Giardia) infections. The present
 CC sequence is a peptide derived from a parent protein used to
 CC construct a savine of the invention.
 CC
 SQ Sequence 30 AA;
 XX
 Query Match 81.3%; Score 161; DB 23; Length 30;
 Best Local Similarity 96.7%; Pred. No. 7.5e-17;
 Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 6 RYVYRDSRDPMLKGPATLWKGAVVYD 35
 Db 1 RYVYRDSRDPXMKGPATLWKGAVVYD 30
 XX
 RESULT 5
 ID AAU84493 standard; Peptide; 30 AA.
 AC AAU84493;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE HIV POL segment 62.
 XX
 KW Savine; vaccine; cancer; viral infection; HIV; hepatitis C virus;
 KW viral infection; human immunodeficiency virus; melanoma;
 KW bacterial infection; Salmonella; Legionella; parasitic infection;

KW Trypanosoma; Toxoplasma; Giardia.
 XX
 OS Human immunodeficiency virus type 1.
 OS Synthetic.
 PN WO200190197-A1.
 PD 29-NOV-2001.
 XX 25-MAY-2001; 2001WO-AU00622.
 XX 26-MAY-2000; 2000AU-0007761.
 PR (AUSU) UNIV AUSTRALIAN NAT.
 PA
 PI Thomson SA, Ramshaw IA;
 DR WPI; 2002-147575/19.
 DR N-PSDB; ABK36332.
 XX
 PT New synthetic polypeptides having several different segments of at
 PT least one parent polypeptide linked together differently compared to
 PT the linkage in the parent polypeptide, for inducing immune response
 PT against a pathogen or cancer
 XX
 PS Example 1; Fig 12; 364pp; English.
 CC The invention relates to a new synthetic polypeptide (I) comprising
 CC several different segments of at least one parent polypeptide linked
 CC together in a different relationship relative to their linkage in the
 CC parent polypeptide to impede, abrogate or otherwise alter at least one
 CC function associated with the parent polypeptide and for inducing an
 CC immune response against a pathogen or cancer. Also included are a
 CC synthetic polynucleotide encoding and a computer system for
 CC designing the synthetic polypeptides. The synthetic polypeptides and
 CC polynucleotides are referred to as a Savine. The synthetic polypeptide is
 CC useful for modulating immune responses preferably directed against a
 CC pathogen or a cancer, (e.g., cancers of the lung, breast, ovary, cervix,
 CC colon, head and neck, pancreas, prostate, stomach, bladder, kidney, bone
 CC liver, oesophagus, brain, testicle, uterus), as potentiating agents.
 CC Compositions comprising the polypeptide may be used in the treatment or
 CC prophylaxis against viral (such as infections caused by HIV (human
 CC immunodeficiency virus), hepatitis, influenza, Japanese encephalitis
 CC virus, Epstein-Barr virus and respiratory syncytial virus), bacterial
 CC (e.g., infections caused by Neisseria, Meningococcal, Haemophilus,
 CC Salmonella, Streptococcal, Legionella and Mycobacterium or parasitic
 CC (e.g., infections caused by Plasmodium, Schistosoma, Leishmania,
 CC Trypanosoma, Toxoplasma and Giardia) infections. The present
 CC sequence is a peptide derived from a parent protein used to
 CC construct a savine of the invention.
 CC
 SQ Sequence 30 AA;
 XX
 Query Match 55.6%; Score 110; DB 23; Length 30;
 Best Local Similarity 95.0%; Pred. No. 3.1e-09;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 KIONFRVYRDSRDPMLKGP 20
 Db 11 KIONFRVYRDSRDPXMKGP 30
 XX
 RESULT 6
 ID ABP24758 standard; Peptide; 15 AA.
 AC ABP24758;
 XX
 DT 15-UTL-2002 (first entry)
 XX
 DE HIV DR super motif pol peptide #125.
 XX
 KW HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr;

KW vpu; vif; tat; cytotoxic T lymphocyte; CTL; immune response; epitope;
 XX antigen; vaccine; HIV infection; immunisation; virucide.
 OS Human immunodeficiency virus type 1.

XX PN WO200124810-A1.
 XX PD 12-APR-2001.

XX PF 05-OCT-2000; 2000WO-US27766.
 XX PR 05-OCT-1999; 99US-0412863.

XX PA (EPIM-) EPIMUNE INC.

XX PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
 XX PI Baker DM, Celis E, Kubo RT, Grey HM;
 XX DR WPI; 2001-354887/37.

XX PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
 XX PT peptide groups, useful for vaccinating against HIV-1 -
 XX PS Claim 32; Page 376; 448pp; English.

XX The present invention describes a composition (I) comprising a prepared
 CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
 CC sequence selected from 51 defined amino acid sequences (AB25347 to
 CC ABP25397). (I) has virucide activity and can be used in vaccines. (I)
 CC may be used for immunising subjects against HIV-1 infections. The use of
 CC group-based vaccines has several advantages over traditional vaccines,
 CC particularly when compared to the use of whole antigens in vaccine
 CC compositions. There is evidence that the immune response to whole
 CC antigens is directed largely toward variable regions of the antigen,
 CC allowing for immune escape due to mutations. The groups for inclusion in
 CC an group-based vaccine may be selected from conserved regions of viral or
 CC tumour-associated antigens, which therefore reduces the likelihood of
 CC escape mutants. Furthermore, immunosuppressive groups that may be present
 CC in whole antigens can be avoided with the use of group-based vaccines.
 CC An additional advantage of an group-based vaccine approach is the ability
 CC to combine selected groups (CTL and HTL), and further, to modify the
 CC composition of the groups, achieving, for example, enhanced
 CC immunogenicity. Accordingly, the immune response can be modulated, as
 CC appropriate, for the target disease. Similar engineering of the response
 CC is not possible with traditional approaches. ABP1501 to ABP25412
 CC represent peptide sequences used in the exemplification of the present
 CC invention.
 XX SQ Sequence 15 AA;

Query Match 45.5%; Score 90; DB 22; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.3e-06;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 13 RDPLMKGPATLWKG 27
 |||:|||||
 Db 1 RDPLMKGPATLWKG 15

RESULT 7
 ABP24701
 ID ABP24701 standard; Peptide; 15 AA.
 XX
 AC ABP24701;
 XX
 DT 15-JUL-2002 (first entry)
 XX
 DE HIV DR super motif pol peptide #68.

XX HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr;
 KW vpu; vif; tat; cytotoxic T lymphocyte; CTL; immune response; epitope;
 XX antigen; vaccine; HIV infection; immunisation; virucide.

OS Human immunodeficiency virus type 1.
 XX
 XX PN WO200124810-A1.

XX PD 12-APR-2001.

XX PF 05-OCT-2000; 2000WO-US27766.
 XX PR 05-OCT-1999; 99US-0412863.

XX PA (EPIM-) EPIMUNE INC.

XX PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
 XX PI Baker DM, Celis E, Kubo RT, Grey HM;
 XX DR WPI; 2001-354887/37.

XX PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
 XX PT peptide groups, useful for vaccinating against HIV-1 -
 XX PS Claim 32; Page 375; 448pp; English.

XX The present invention describes a composition (I) comprising a prepared
 CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
 CC sequence selected from 51 defined amino acid sequences (AB25347 to
 CC ABP25397). (I) has virucide activity and can be used in vaccines. (I)
 CC may be used for immunising subjects against HIV-1 infections. The use of
 CC group-based vaccines has several advantages over traditional vaccines,
 CC particularly when compared to the use of whole antigens in vaccine
 CC compositions. There is evidence that the immune response to whole
 CC antigens is directed largely toward variable regions of the antigen,
 CC allowing for immune escape due to mutations. The groups for inclusion in
 CC an group-based vaccine may be selected from conserved regions of viral or
 CC tumour-associated antigens, which therefore reduces the likelihood of
 CC escape mutants. Furthermore, immunosuppressive groups that may be present
 CC in whole antigens can be avoided with the use of group-based vaccines.
 CC An additional advantage of an group-based vaccine approach is the ability
 CC to combine selected groups (CTL and HTL), and further, to modify the
 CC composition of the groups, achieving, for example, enhanced
 CC immunogenicity. Accordingly, the immune response can be modulated, as
 CC appropriate, for the target disease. Similar engineering of the response
 CC is not possible with traditional approaches. ABP1501 to ABP25412
 CC represent peptide sequences used in the exemplification of the present
 CC invention.
 XX SQ Sequence 15 AA;

Query Match 44.4%; Score 88; DB 22; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2.6e-06;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 13 RDPLMKGPATLWKG 27
 |||:|||||
 Db 1 RDPLMKGPATLWKG 15

RESULT 8
 ABP25020
 ID ABP25020 standard; Peptide; 15 AA.
 XX
 AC ABP25020;
 XX
 DT 15-JUL-2002 (first entry)
 XX
 DE HIV DR 3b motif pol peptide #11.

XX HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr;
 KW vpu; vif; tat; cytotoxic T lymphocyte; CTL; immune response; epitope;
 XX antigen; vaccine; HIV infection; immunisation; virucide.

OS Human immunodeficiency virus type 1.
 XX
 XX PN WO200124810-A1.

XX 12-APR-2001.
PD 05-OCT-2000; 2000WO-US27766.
XX PF 05-OCT-1999; 99US-0412863.
XX PR 05-OCT-1999; 99US-0412863.
XX PA (EPIM-) EPIMMUNE INC.
XX PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
XX PI Baker DM, Cells E, Kubo RT, Grey HM;
XX DR WPI; 2001-354887/37.
XX PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
XX PT peptide groups, useful for vaccinating against HIV-1 -
XX PS Claim 32; Page 408; 448pp; English.
XX The present invention describes a composition (I) comprising a prepared
CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
CC sequence selected from 51 defined amino acid sequences (AB125347 to
CC ABP25397). (I) has virucide activity and can be used in vaccines. (I)
CC may be used for immunising subjects against HIV-1 infections. The use of
CC group-based vaccines has several advantages over traditional vaccines,
CC particularly when compared to the use of whole antigens in vaccine
CC compositions. There is evidence that the immune response to whole
CC antigens is directed largely toward variable regions of the antigen,
CC allowing for immune escape due to mutations. The groups for inclusion in
CC an group-based vaccine may be selected from conserved regions of viral or
CC tumour-associated antigens, which therefore reduces the likelihood of
CC escape mutants. Furthermore, immunosuppressive groups that may be present
CC in whole antigens can be avoided with the use of group-based vaccines.
CC An additional advantage of an group-based vaccine approach is the ability
CC to combine selected groups (CTL and HTL), and further, to modify the
CC composition of the groups, achieving, for example, enhanced
CC immunogenicity. Accordingly, the immune response can be modulated, as
CC appropriate, for the target disease. Similar engineering of the response
CC is not possible with traditional approaches. ABP11501 to ABP25412
CC represent peptide sequences used in the exemplification of the present
CC invention.
XX SQ Sequence 15 AA;
XX Query Match 44.4%; Score 86; DB 22; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 2.6e-06;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 5 FRVYRDSRDPIMKG 19
Db 1 FRVYRDSRDPIMKG 15
RESULT 9
ABP24677
ID ABP24677 standard; Peptide; 15 AA.
XX AC ABP24677;
XX DT 15-JUL-2002 (first entry)
XX DE HIV DR super motif pol peptide #44.
XX HIV, HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr;
XX vpu; vif; tat; cytototoxic T lymphocyte; CTL; immune response; epitope;
XX antigen; vaccine; HIV infection; immunisation; virucide.
XX OS Human immunodeficiency virus type 1.
XX PN WO200124810-A1.
XX PD 12-APR-2001.
XX

PF 05-OCT-2000; 2000WO-US27766.
XX 05-OCT-1999; 99US-0412863.
XX PR 05-OCT-1999; 99US-0412863.
XX PA (EPIM-) EPIMMUNE INC.
XX PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
XX PI Baker DM, Cells E, Kubo RT, Grey HM;
XX DR WPI; 2001-354887/37.
XX PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
XX PT peptide groups, useful for vaccinating against HIV-1 -
XX PS Claim 32; Page 374; 448pp; English.
XX The present invention describes a composition (I) comprising a prepared
CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
CC sequence selected from 51 defined amino acid sequences (AB125347 to
CC ABP25397). (I) has virucide activity and can be used in vaccines. (I)
CC may be used for immunising subjects against HIV-1 infections. The use of
CC group-based vaccines has several advantages over traditional vaccines,
CC particularly when compared to the use of whole antigens in vaccine
CC compositions. There is evidence that the immune response to whole
CC antigens is directed largely toward variable regions of the antigen,
CC allowing for immune escape due to mutations. The groups for inclusion in
CC an group-based vaccine may be selected from conserved regions of viral or
CC tumour-associated antigens, which therefore reduces the likelihood of
CC escape mutants. Furthermore, immunosuppressive groups that may be present
CC in whole antigens can be avoided with the use of group-based vaccines.
CC An additional advantage of an group-based vaccine approach is the ability
CC to combine selected groups (CTL and HTL), and further, to modify the
CC composition of the groups, achieving, for example, enhanced
CC immunogenicity. Accordingly, the immune response can be modulated, as
CC appropriate, for the target disease. Similar engineering of the response
CC is not possible with traditional approaches. ABP11501 to ABP25412
CC represent peptide sequences used in the exemplification of the present
CC invention.
XX SQ Sequence 15 AA;
XX Query Match 43.4%; Score 86; DB 22; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 5.2e-06;
XX Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 4 NFRVYRDSRDPIMK 18
Db 1 NFRVYRDSRDPIMK 15
RESULT 10
ABP25016
ID ABP25016 standard; Peptide; 15 AA.
XX AC ABP25016;
XX DT 15-JUL-2002 (first entry)
XX DE HIV DR 3b motif pol peptide #7.
XX HIV, HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr;
XX vpu; vif; tat; cytototoxic T lymphocyte; CTL; immune response; epitope;
XX antigen; vaccine; HIV infection; immunisation; virucide.
XX OS Human immunodeficiency virus type 1.
XX PN WO200124810-A1.
XX PD 12-APR-2001.
XX PF 05-OCT-2000; 2000WO-US27766.
XX PR 05-OCT-1999; 99US-0412863.
XX

XX (EPTM-) EPIMUNE INC.
XX
XX

PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
PI Baker DM, Celis E, Kubo RT, Grey HM;
XX
XX

DR WPI: 2001-35487/37.
XX

PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
PT Peptide groups, useful for vaccinating against HIV-1
XX
XX

PS Claim 32; Page 408; 448pp; English.
XX

CC The present invention describes a composition (I) comprising a prepared
CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
CC sequence selected from 51 defined amino acid sequences (AB25347 to
CC AB25397). (I) has virucide activity and can be used in vaccines. (I)
CC may be used for immunizing subjects against HIV-1 infections. (I)
CC group-based vaccines has several advantages over traditional vaccines,
CC particularly when compared to the use of whole antigens in vaccine
CC compositions. There is evidence that the immune response to whole
CC antigens is directed largely toward variable regions of the antigen,
CC allowing for immune escape due to mutations. The groups for inclusion in
CC an group-based vaccine may be selected from conserved regions of viral or
CC tumour-associated antigens, which therefore reduces the likelihood of
CC in whole antigens can be avoided with the use of group-based vaccines.
CC An additional advantage of an group-based vaccine approach is the ability
CC to combine selected groups (CTL and HTL), and further, to modify the
CC composition of the groups, achieving, for example, enhanced
CC immunogenicity. Accordingly, the immune response can be modulated, as
CC appropriate, for the target disease. Similar engineering of the response
CC is not possible with traditional approaches. ABP11501 to ABP25412
CC represent peptide sequences used in the exemplification of the present
CC invention.
XX

SO Sequence 15 AA;

Query Match Best Local Similarity 43.4%; Score 86; DB 22; Length 15;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 5 FRVYRDSRDLPLWKG 19
DB 1 FRVYRDSRDLPLWKG 15

RESULT 11

AAU84495

XX AAU84495 standard; Peptide; 30 AA.

AC AAU84495;

DT 08-MAY-2002 (first entry)

DE HIV POL segment 64.

KM Savine; vaccine; cancer; viral infection; HIV; hepatitis C virus;
KM viral infection; human immunodeficiency virus; melanoma;
KM bacterial infection; Salmonella; Legionella; parasitic infection;
KM Trypanosoma; Toxoplasma; Giardia.
XX

OS Human immunodeficiency virus type 1.
OS Synthetic.

PN WO200190197-A1.

PD 29-NOV-2001.

PF 25-MAY-2001; 2001WO-AU00622.

PR 26-MAY-2000; 2000AU-0007761.
XX

PA (AUSU) UNIV AUSTRALIAN NAT.
XX
XX

PI Thomson SA, Ramsdell IA;
XX

DR WPI: 2002-147575/19.
XX

DR N-FSDB; ABK36334.
XX

PT New synthetic polypeptides having several different segments of at
PT least one parent polypeptide linked together differently compared to
PT the linkage in the parent polypeptide, for inducing immune response
XX
XX

PS Example 1; Fig 12; 364pp; English.
XX

CC The invention relates to a new synthetic polypeptide (I) comprising
CC several different segments of at least one parent polypeptide linked
CC together in a different relationship relative to their linkage in the
CC parent polypeptide to impede, abrogate or otherwise alter at least one
CC function associated with the parent polypeptide and for inducing an
CC immune response against a pathogen or cancer. Also included are a
CC synthetic polynucleotide encoding and a computer system for
CC designing the synthetic polypeptides. The synthetic polypeptides and
CC polynucleotides are referred to as a Savine. The synthetic polypeptide is
CC useful for modulating immune responses preferably directed against a
CC pathogen or a cancer. (e.g., cancers of the lung, breast, ovary, cervix,
CC colon, head and neck, pancreas, prostate, stomach, bladder, kidney, bone
CC liver, oesophagus, brain, testicle, uterus), as potentiating agents.
CC Compositions comprising the polypeptide may be used in the treatment or
CC prophylaxis against viral (such as infections caused by HIV (human
CC virus, Epstein-Barr virus and respiratory syncytial virus), bacterial
CC (e.g., infections caused by Neisseria, Meningococcal, Haemophilus,
CC Salmonella, Streptococcal, Legionella, and Mycobacterium) or parasitic
CC (e.g., infections caused by Plasmodium, Schistosoma, Leishmania,
CC Trypanosoma, Toxoplasma and Giardia) infections. The present
CC sequence is a peptide derived from a parent protein used to
CC construct a Savine of the invention.
XX

SO Sequence 30 AA;

Query Match Best Local Similarity 41.9%; Score 83; DB 23; Length 30;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 21 AKLWKGSGAVVQDN 36
DB 1 AKLWKGSGAVVQDN 16

RESULT 12

AAW85346

XX AAW85346 standard; peptide; 15 AA.

AC AAW85346;

DT 16-FEB-1999 (first entry)

DE Helper T-cell class II peptide derived from POL protein.

KM Helper T-cell peptide; human leucocyte antigen; HLA; DR4; DR1;
KM DR7; cytotoxic T lymphocyte; CTL; hepatitis; autoimmune disease;
KM acquired immune deficiency syndrome; malaria; cancer;
KM allograft rejection; allergy; Lyme disease; hepatitis;
KM post-streptococcal endocarditis; glomerulonephritis;
KM food hypersensitivity.
XX

OS Synthetic.

OS Human immunodeficiency virus type 1.

PN WO9832456-A1.

PD 30-JUL-1998.
XX

PF 23-JAN-1998; 98WO-US01373.
 XX
 PR 07-FEB-1997; 97US-0037432.
 PR 23-JAN-1997; 97US-0036713.
 XX
 PA (EPIM-) EPIMMUNE INC.
 XX
 PI Sette A, Sidney J, Southwood S;
 XX
 DR WPI; 1998-427679/36.
 XX
 PT Composition containing peptide that induces cytotoxic T lymphocyte
 PT response, and helper peptide - can bind to human leucocyte antigen
 PT alleles, used to treat or prevent cancers, parasitic infections and
 PT autoimmune disease
 XX
 PS Disclosure; Page 41; 51pp; English.
 XX
 CC AAM85284-451 represent helper T-cell class II peptides, which can bind
 CC to the human leucocyte antigens (HLA) DR4w4, DRI and DR7. The peptides
 CC are used in the course of the invention. The specification describes
 CC peptides that induce a cytotoxic T lymphocyte (CTL) response, and
 CC T-helper peptides, that are used together to generate a CTL response for
 CC the treatment or prevention of viral, fungal, bacterial or parasitic
 CC infections (e.g. hepatitis, acquired immune deficiency syndrome or
 CC malaria) or cancer (e.g. renal or cervical carcinoma, lymphoma, prostate
 CC cancer or condyloma acuminatum). Helper T-cell peptides may be used
 CC alone to induce a helper T cell response, e.g. in cases of autoimmune
 CC disease, allograft rejection, allergy, Lyme disease, hepatitis,
 CC post-streptococcal endocarditis, glomerulonephritis and food
 CC hypersensitivity.
 XX
 SQ Sequence 15 AA;
 XX

Query Match 39.9%; Score 79; DB 19; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.7e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 22 KILMKSGAVVIODN 36
 Db 1 KILMKSGAVVIODN 15

RESULT 13
 ID AABP24643 standard; Peptide; 15 AA.
 AC AABP24643;
 XX
 DT 15-JUL-2002 (first entry)
 XX
 DE HIV DR super motif pol peptide #10.
 XX
 KW HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr;
 KW vif; tat; cytototoxic T lymphocyte; CTL; immune response; epitope;
 KW antigen; vaccine; HIV infection; immunisation; virucide.
 XX
 OS Human immunodeficiency virus type 1.
 XX
 PN WO200124810-A1.
 PD 12-APR-2001.
 XX
 PF 05-OCT-2000; 2000WO-US27766.
 XX
 PR 05-OCT-1999; 99US-0412863.
 XX
 PA (EPIM-) EPIMMUNE INC.
 XX
 PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
 PI Baker DM, Cells E, Kubo RT, Grey HM;
 XX
 DR WPI; 2001-354887/37.

XX
 PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
 PT peptide groups, useful for vaccinating against HIV-1 -
 XX
 PS Claim 32; Page 374; 448pp; English.
 XX

CC The present invention describes a composition (I) comprising a prepared
 CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
 CC sequence selected from 51 defined amino acid sequences (AB125347 to
 CC ABP25397). (II) has virucide activity and can be used in vaccines. (I)
 CC may be used for immunising subjects against HIV-1 infections. The use of
 CC group-based vaccines has several advantages over traditional vaccines,
 CC particularly when compared to the use of whole antigens in vaccine
 CC compositions. There is evidence that the immune response to whole
 CC antigens is directed largely toward variable regions of the antigen,
 CC allowing for immune escape due to mutations. The groups for inclusion in
 CC an group-based vaccine may be selected from conserved regions of viral or
 CC tumour-associated antigens, which therefore reduces the likelihood of
 CC escape mutants. Furthermore, immunosuppressive groups that may be present
 CC in whole antigens can be avoided with the use of group-based vaccines.
 CC An additional advantage of an group-based vaccine approach is the ability
 CC to combine selected groups (CTL and HTL), and further, to modify the
 CC composition of the groups, achieving, for example, enhanced
 CC immunogenicity. Accordingly, the immune response can be modulated, as
 CC appropriate, for the target disease. Similar engineering of the response
 CC is not possible with traditional approaches. ABP1501 to ABP25412
 CC represent peptide sequences used in the exemplification of the present
 CC invention.
 XX
 SQ Sequence 15 AA;
 XX

Query Match 39.9%; Score 79; DB 22; Length 15;
 Best Local Similarity 100.0%; Pred. No. 5.7e-05;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 22 KILMKSGAVVIODN 36
 Db 1 KILMKSGAVVIODN 15

RESULT 14
 ID AAR03899 standard; peptide; 15 AA.
 AC AAR03899;
 XX
 DT 16-FEB-1993 (first entry)
 XX
 DE HIV-antibody reactive peptide (2).
 XX
 KW HIV; diagnosis.
 XX
 OS Synthetic.
 XX
 PN EP362915-A.
 PD 11-APR-1990.
 XX
 PF 07-SEP-1989; 89EP-0202258.
 XX
 PR 09-SEP-1988; 88NL-0002217.
 XX
 PA (ALKU) AKZO NV.
 XX
 PI Hellings JA, Schalken JJ, Sprengers ED;
 PI WPI; 1990-109271/15.
 XX
 DR
 XX
 PT New synthetic oligopeptide cpds. reactive with HIV antibodies -
 PT useful as diagnostic reagents are non infectious and safe to use
 XX
 PS Claim 3; Page 5 + Fig 2; 7pp; English.
 XX

CC The peptides given in AAR03898-900 react immunochemically with
 CC antibodies directed against HIV. They are suitable for use in a
 CC diagnostic method for determining the presence of HIV or HIV-
 CC antibodies in a test fluid. In contrast to the native HIV, the
 CC peptides have the great advantage that these are of a safe non-
 CC infectious origin. They are made by standard (esp. solid phase)
 CC methods of peptide synthesis, or by recombinant DNA techniques.

XX
 SQ Sequence 15 AA;

Query Match

Best Local Similarity 35.4%; Score 70; DB 11; Length 15;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1 KIQNFRVYRDSRD 14
 |||||
 Db 2 KIQNFRVYRDSRN 15

RESULT 15

ABP24663
 ID ABP24663 standard; Peptide; 15 AA.

AC ABP24663;

DT 15-JUL-2002 (first entry)

EX HIV DR super motif pol peptide #30.

DE HIV DR super motif pol peptide #30.

XX HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr;
 KW vpr; tat; cytoxic T lymphocyte; CTL; immune response; epitope;
 KW antigen; vaccine; HIV infection; immunisation; virucide.

XX Human immunodeficiency virus type 1.

OS WO200124810-A1.

XX 12-APR-2001.

PD 05-OCT-2000; 2000WO-US27766.

PF 05-OCT-1999; 99US-0412863.

PR (EPI-M) EPIMUNE INC.

XX Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;
 PI Baker DM, Celis E, Kudo RT, Grey HM;
 DR WPI; 2001-354887/37.

XX Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)
 PT peptide groups, useful for vaccinating against HIV-1 -
 PS Claim 32; Page 374; 448pp; English.

CC The present invention describes a composition (I) comprising a prepared
 CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid
 CC sequence selected from 51 defined amino acid sequences (ABU25347 to
 CC ABP25397). (I) has virucide activity and can be used in vaccines. (I)
 CC may be used for immunising subjects against HIV-1 infections. The use of
 CC group-based vaccines has several advantages over traditional vaccines,
 CC particularly when compared to the use of whole antigens in vaccine
 CC compositions. There is evidence that the immune response to whole
 CC antigens is directed largely toward variable regions of the antigen,
 CC allowing for immune escape due to mutations. The groups for inclusion in
 CC an group-based vaccine may be selected from conserved regions of viral or
 CC tumour-associated antigens, which therefore reduces the likelihood of
 CC escape mutants. Furthermore, immunosuppressive groups that may be present
 CC in whole antigens can be avoided with the use of group-based vaccines.
 CC An additional advantage of an group-based vaccine approach is the ability
 CC to combine selected groups (CTL and HTL), and further, to modify the
 CC composition of the groups, achieving, for example, enhanced
 CC immunogenicity. Accordingly, the immune response can be modulated, as

CC appropriate, for the target disease. Similar engineering of the response
 CC is not possible with traditional approaches. ABP11501 to ABP25412
 CC represent peptide sequences used in the exemplification of the present
 CC invention.

XX
 SQ Sequence 15 AA;

Query Match

Best Local Similarity 34.8%; Score 69; DB 22; Length 15;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 KIQNFRVYRDSR 13
 |||||
 Db 3 KIQNFRVYRDSR 15

Search completed: May 6, 2003, 14:57:23
 Job time : 35 secs